Lack	O
of	O
T-cell-mediated	O
recognition	O
of	O
the	O
fusion	O
region	O
of	O
the	O
pml/RAR-alpha	B-protein
hybrid	I-protein
protein	I-protein
by	O
lymphocytes	B-cell_type
of	O
acute	O
promyelocytic	O
leukemia	O
patients	O
.	O

In	O
previous	O
studies	O
,	O
it	O
was	O
shown	O
that	O
the	O
fusion	O
region	O
of	O
the	O
pml/RAR-alpha	B-protein
protein	I-protein
,	O
expressed	O
by	O
acute	B-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
(	I-cell_line
APL	I-cell_line
)	I-cell_line
cells	I-cell_line
,	O
can	O
be	O
specifically	O
recognized	O
in	O
vitro	O
by	O
donor	O
(	O
D.	O
E.	O
)	O
CD4	B-cell_line
T	I-cell_line
cells	I-cell_line
in	O
a	O
HLA	B-protein
class	I-protein
II	I-protein
DR11-restricted	O
fashion	O
.	O

We	O
present	O
here	O
the	O
results	O
on	O
the	O
recognition	O
of	O
several	O
pml/RAR-alpha	O
peptides	O
by	O
APL	O
patients	O
expressing	O
HLA	B-protein
DR11	I-protein
.	O

The	O
in	O
vitro	O
immunization	O
of	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
from	O
four	O
patients	O
in	O
remission	O
(	O
S.R.	O
,	O
F.R.	O
,	O
M.M.	O
,	O
P.	O
G.	O
)	O
with	O
BCR1/25	O
,	O
a	O
25-mer	O
pml/	O
RAR-alpha	B-protein
,	O
did	O
not	O
elicit	O
either	O
a	O
polyclonal	O
or	O
a	O
clonal	O
immune	O
response	O
specific	O
to	O
the	O
peptide	O
.	O

We	O
then	O
generated	O
new	O
donor	O
anti-pml/RAR-alpha	B-cell_line
CD4	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
.	O

These	O
clones	O
were	O
tested	O
for	O
their	O
recognition	O
of	O
BCR1/25	O
.	O

One	O
clone	O
(	O
C3/5	B-cell_line
,	I-cell_line
CD3	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
,	I-cell_line
CD4	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
,	I-cell_line
CD8	I-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
)	O
was	O
selected	O
for	O
further	O
analysis	O
.	O

Clone	B-cell_line
C3/5	I-cell_line
showed	O
specific	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
cytokine	O
(	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
)	O
production	O
when	O
challenged	O
with	O
autologous	B-cell_line
lymphoblastic	I-cell_line
cell	I-cell_line
lines	I-cell_line
pulsed	O
with	O
peptide	O
BCR1/25	O
.	O

C3/5	B-cell_line
cells	I-cell_line
developed	O
specific	O
proliferation	O
and	O
cytotoxicity	O
when	O
challenged	O
with	O
peptide-pulsed	B-cell_line
lymphoblastic	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
from	O
the	O
four	O
DR11	O
(	O
+	O
)	O
APL	O
patients	O
.	O

APL	B-cell_type
blasts	I-cell_type
,	O
available	O
only	O
from	O
patients	O
F.R.	O
and	O
P.G.	O
,	O
were	O
not	O
lysed	O
by	O
C3/5	B-cell_line
and	O
were	O
unable	O
to	O
present	O
peptide	O
BCR1/25	O
.	O

Incubation	O
of	O
APL	B-cell_line
cells	I-cell_line
with	O
IFN-gamma	B-protein
failed	O
to	O
induce	O
HLA	B-protein
class	I-protein
II	I-protein
molecules	I-protein
and	O
recognition	O
by	O
the	O
C3/5	B-cell_line
clone	I-cell_line
.	O

Since	O
APL	B-cell_line
cells	I-cell_line
do	O
not	O
express	O
HLA	B-protein
class	I-protein
II	I-protein
molecules	I-protein
,	O
we	O
tested	O
in	O
two	O
donors	O
(	O
D.E.	O
and	O
C.H.R.	O
)	O
and	O
in	O
patients	O
S.R.and	O
P.G.whether	O
the	O
use	O
of	O
9-mer	O
peptides	O
(	O
BCR1/9	O
)	O
would	O
generate	O
a	O
CD8	B-protein
/HLA	B-protein
class	I-protein
I	I-protein
-restricted	O
response	O
.	O

No	O
peptide-specific	B-cell_line
T-cell	I-cell_line
line	I-cell_line
or	O
clone	O
could	O
be	O
generated	O
from	O
both	O
donors	O
and	O
patients	O
.	O

These	O
findings	O
are	O
discussed	O
in	O
relation	O
to	O
possible	O
therapeutic	O
approaches	O
to	O
the	O
immunotherapy	O
of	O
APL	O
.	O

Vol	NULL
.	NULL

2	NULL
,	NULL
593-600	NULL
,	NULL
March	NULL
1996	NULL
Clinical	NULL
Cancer	NULL
Research	NULL
593	NULL
Lack	NULL
of	NULL
T-Cell-mediated	NULL
Recognition	NULL
of	NULL
the	NULL
Fusion	NULL
Region	NULL
of	NULL
the	NULL
pmIl/RAR-	NULL
«	NULL
Hybrid	NULL
Protein	NULL
by	NULL
Lymphocytes	NULL
of	NULL
Acute	NULL
Promyelocytic	NULL
Leukemia	NULL
Patients	NULL
'	NULL
Said	NULL
Dermime	NULL
,	NULL
Carla	NULL
Bertazzoli	NULL
,	NULL
Edoardo	NULL
Marchesi	NULL
,	NULL
Fernando	NULL
Ravagnani	NULL
,	NULL
Kurt	NULL
Blaser	NULL
,	NULL
Gian	NULL
Marco	NULL
Corneo	NULL
,	NULL
Enrico	NULL
Pogliani	NULL
,	NULL
Giorgio	NULL
Parmiani	NULL
,	NULL
and	NULL
Carlo	NULL
Division	NULL
of	NULL
Experimental	NULL
Oncology	NULL
D	NULL
and	NULL
Blood	NULL
Bank	NULL
,	NULL
Istituto	NULL
Nazionale	NULL
Tumori	NULL
,	NULL
Via	NULL
Venezian	NULL
1	NULL
,	NULL
20133	NULL
Milan	NULL
,	NULL
Italy	NULL
[	NULL
S.	NULL
D..	NULL
C.	NULL
B.	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
F.	NULL
R.	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
C.	NULL
G-P.	NULL
)	NULL
]	NULL
;	NULL
Swiss	NULL
Institute	NULL
of	NULL
Allergy	NULL
and	NULL
Asthma	NULL
Research	NULL
.	NULL

Davos	NULL
,	NULL
Switzerland	NULL
[	NULL
K	NULL
.	NULL

B	NULL
.	NULL
)	NULL

;	NULL
and	NULL
Section	NULL
of	NULL
Hematology	NULL
,	NULL
University	NULL
of	NULL
Milan	NULL
,	NULL
S.	NULL
Gerardo	NULL
Hospital	NULL
,	NULL
Monza	NULL
,	NULL
Italy	NULL
[	NULL
G.	NULL
M.	NULL
C.	NULL
,	NULL
E.	NULL
P.	NULL
]	NULL
ABSTRACT	NULL
In	NULL
previous	NULL
studies	NULL
,	NULL
it	NULL
was	NULL
shown	NULL
that	NULL
the	NULL
fusion	NULL
region	NULL
of	NULL
the	NULL
pmI/RAR-	NULL
«	NULL
protein	NULL
,	NULL
expressed	NULL
by	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
APL	NULL
)	NULL
cells	NULL
,	NULL
can	NULL
be	NULL
specifically	NULL
recognized	NULL
in	NULL
vitro	NULL
by	NULL
donor	NULL
(	NULL
D.	NULL
E.	NULL
)	NULL
CD4	NULL
T	NULL
cells	NULL
in	NULL
a	NULL
HLA	NULL
class	NULL
II	NULL
DR11-restricted	NULL
fashion	NULL
.	NULL

We	NULL
present	NULL
here	NULL
the	NULL
results	NULL
on	NULL
the	NULL
recognition	NULL
of	NULL
several	NULL
pmIl/RAR-	NULL
«	NULL
peptides	NULL
by	NULL
APL	NULL
patients	NULL
expressing	NULL
HLA	NULL
DR11	NULL
.	NULL

The	NULL
in	NULL
vitro	NULL
immunization	NULL
of	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
from	NULL
four	NULL
patients	NULL
in	NULL
remission	NULL
(	NULL
S.	NULL
R.	NULL
,	NULL
F.	NULL
R.	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
P.	NULL
G.	NULL
)	NULL
with	NULL
BCR1/25	NULL
,	NULL
a	NULL
25-mer	NULL
pmV/	NULL
RAR-	NULL
«	NULL
,	NULL
did	NULL
not	NULL
elicit	NULL
either	NULL
a	NULL
polyclonal	NULL
or	NULL
a	NULL
clonal	NULL
immune	NULL
response	NULL
specific	NULL
to	NULL
the	NULL
peptide	NULL
.	NULL

We	NULL
then	NULL
generated	NULL
new	NULL
donor	NULL
anti-pmI/RAR-	NULL
«	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
.	NULL

These	NULL
clones	NULL
were	NULL
tested	NULL
for	NULL
their	NULL
recognition	NULL
of	NULL
BCR1/25	NULL
.	NULL

One	NULL
clone	NULL
(	NULL
C3/5	NULL
,	NULL
CD3*	NULL
,	NULL
CD4*	NULL
,	NULL
CD87	NULL
)	NULL
was	NULL
selected	NULL
for	NULL
further	NULL
analysis	NULL
.	NULL

Clone	NULL
C3/5	NULL
showed	NULL
specific	NULL
proliferation	NULL
,	NULL
cytotoxicity	NULL
,	NULL
and	NULL
cytokine	NULL
(	NULL
tumor	NULL
necrosis	NULL
factor	NULL
&	NULL
,	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
)	NULL
production	NULL
when	NULL
challenged	NULL
with	NULL
autologous	NULL
lymphoblastic	NULL
cell	NULL
lines	NULL
pulsed	NULL
with	NULL
peptide	NULL
BCR1/25	NULL
.	NULL

C3/5	NULL
cells	NULL
developed	NULL
specific	NULL
proliferation	NULL
and	NULL
cytotoxicity	NULL
when	NULL
challenged	NULL
with	NULL
peptide-pulsed	NULL
lymphoblastic	NULL
cell	NULL
lines	NULL
and	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
from	NULL
the	NULL
four	NULL
DR11*	NULL
APL	NULL
patients	NULL
.	NULL

APL	NULL
blasts	NULL
,	NULL
available	NULL
only	NULL
from	NULL
patients	NULL
F.	NULL
R.	NULL
and	NULL
P.	NULL
G.	NULL
,	NULL
were	NULL
not	NULL
lysed	NULL
by	NULL
C3/5	NULL
and	NULL
were	NULL
unable	NULL
to	NULL
present	NULL
peptide	NULL
BCR1/25	NULL
.	NULL

Incubation	NULL
of	NULL
APL	NULL
cells	NULL
with	NULL
IFN-y	NULL
failed	NULL
to	NULL
induce	NULL
HLA	NULL
class	NULL
II	NULL
molecules	NULL
and	NULL
recognition	NULL
by	NULL
the	NULL
C3/5	NULL
clone	NULL
.	NULL

Since	NULL
APL	NULL
cells	NULL
do	NULL
not	NULL
express	NULL
HLA	NULL
class	NULL
II	NULL
molecules	NULL
,	NULL
we	NULL
tested	NULL
in	NULL
two	NULL
donors	NULL
(	NULL
D.	NULL
E.	NULL
and	NULL
C.	NULL
H.	NULL
R.	NULL
)	NULL
and	NULL
in	NULL
patients	NULL
S.	NULL
R.	NULL
and	NULL
P.	NULL
G.	NULL
whether	NULL
the	NULL
use	NULL
of	NULL
9-mer	NULL
peptides	NULL
(	NULL
BCR1/9	NULL
)	NULL
would	NULL
generate	NULL
a	NULL
CD8/HLA	NULL
class	NULL
I-restricted	NULL
response	NULL
.	NULL

No	NULL
peptide-specific	NULL
T-cell	NULL
line	NULL
or	NULL
clone	NULL
Received	NULL
6/15/95	NULL
;	NULL
revised	NULL
10/18/95	NULL
;	NULL
accepted	NULL
11/28/95	NULL
.	NULL
'	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
the	NULL
Italian	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
,	NULL
the	NULL
Italy-United	NULL
States	NULL
Program	NULL
on	NULL
Therapy	NULL
of	NULL
Tumors	NULL
(	NULL
Grant	NULL
531	NULL
23.12.87	NULL
)	NULL
,	NULL
and	NULL
a	NULL
donation	NULL
from	NULL
CEVA	NULL
SpA	NULL
,	NULL
Monza	NULL
.	NULL

*	NULL
To	NULL
whom	NULL
requests	NULL
for	NULL
reprints	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

Phone	NULL
:	NULL
39.2.239-0207	NULL
;	NULL
Fax	NULL
:	NULL
39.2.236-2692.	NULL
could	NULL
be	NULL
generated	NULL
from	NULL
both	NULL
donors	NULL
and	NULL
patients	NULL
.	NULL

These	NULL
findings	NULL
are	NULL
discussed	NULL
in	NULL
relation	NULL
to	NULL
possible	NULL
therapeutic	NULL
approaches	NULL
to	NULL
the	NULL
immunotherapy	NULL
of	NULL
APL	NULL
.	NULL

INTRODUCTION	NULL
The	NULL
pmIl/RAR-a	NULL
«	NULL
fusion	NULL
protein	NULL
,	NULL
specifically	NULL
expressed	NULL
in	NULL
APL	NULL
(	NULL
1-4	NULL
)	NULL
cells	NULL
,	NULL
creates	NULL
a	NULL
new	NULL
tumor-specific	NULL
amino	NULL
acid	NULL
sequence	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
a	NULL
25-mer	NULL
peptide	NULL
(	NULL
BCR1/25	NULL
)	NULL
,	NULL
encompassing	NULL
the	NULL
fusion	NULL
region	NULL
,	NULL
contains	NULL
an	NULL
antigenic	NULL
site	NULL
(	NULL
ab-sent	NULL
in	NULL
the	NULL
normal	NULL
parent	NULL
molecules	NULL
)	NULL
recognizable	NULL
by	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
of	NULL
a	NULL
healthy	NULL
donor	NULL
(	NULL
D.	NULL
E.	NULL
)	NULL
in	NULL
an	NULL
HLA	NULL
DRI1-restricted	NULL
fashion	NULL
on	NULL
presentation	NULL
by	NULL
autologous	NULL
APCs	NULL
(	NULL
5	NULL
,	NULL
6	NULL
)	NULL
.	NULL

Antipeptide	NULL
CD4	NULL
clones	NULL
also	NULL
recognize	NULL
pmI/RAR-a-transfected	NULL
LCLs	NULL
(	NULL
6	NULL
)	NULL
.	NULL

The	NULL
possible	NULL
recognition	NULL
of	NULL
the	NULL
pmI/RAR-a	NULL
«	NULL
protein	NULL
by	NULL
T	NULL
lymphocytes	NULL
of	NULL
APL	NULL
patients	NULL
would	NULL
open	NULL
the	NULL
possibility	NULL
of	NULL
directing	NULL
the	NULL
patient	NULL
's	NULL
immune	NULL
system	NULL
against	NULL
the	NULL
leukemic	NULL
cells	NULL
through	NULL
the	NULL
recognition	NULL
of	NULL
a	NULL
tumor-specific/transformation-related	NULL
molecule	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Although	NULL
binding	NULL
motifs	NULL
for	NULL
most	NULL
DR	NULL
molecules	NULL
were	NULL
not	NULL
known	NULL
at	NULL
the	NULL
time	NULL
of	NULL
the	NULL
study	NULL
,	NULL
our	NULL
previous	NULL
data	NULL
(	NULL
6	NULL
)	NULL
indicated	NULL
that	NULL
DR	NULL
11	NULL
functions	NULL
as	NULL
a	NULL
restriction	NULL
element	NULL
in	NULL
this	NULL
case	NULL
.	NULL

For	NULL
this	NULL
reason	NULL
,	NULL
we	NULL
focused	NULL
on	NULL
the	NULL
analysis	NULL
of	NULL
DR1	NULL
1	NULL
*	NULL
of	NULL
DR11	NULL
APL	NULL
patients	NULL
.	NULL

In	NULL
the	NULL
present	NULL
work	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
in	NULL
vitro	NULL
immune	NULL
response	NULL
of	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
from	NULL
four	NULL
HLA	NULL
DRI	NULL
1	NULL
*	NULL
APL	NULL
patients	NULL
to	NULL
several	NULL
pmI/RAR-a	NULL
«	NULL
peptides	NULL
.	NULL

PATIENTS	NULL
AND	NULL
METHODS	NULL
Patients	NULL
Four	NULL
APL	NULL
patients	NULL
were	NULL
studied	NULL
after	NULL
informed	NULL
consent	NULL
was	NULL
obtained	NULL
.	NULL

Three	NULL
patients	NULL
(	NULL
F.	NULL
R.	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
)	NULL
were	NULL
in	NULL
first	NULL
remission	NULL
,	NULL
and	NULL
one	NULL
patient	NULL
(	NULL
M.	NULL
M.	NULL
)	NULL
was	NULL
in	NULL
second	NULL
remission	NULL
.	NULL

Two	NULL
patients	NULL
(	NULL
S.	NULL
R.	NULL
and	NULL
M.	NULL
M.	NULL
)	NULL
underwent	NULL
autologous	NULL
bone	NULL
marrow	NULL
|	NULL
transplantation	NULL
:	NULL
;	NULL
the	NULL
conditioning	NULL
regimen	NULL
included	NULL
high-dose	NULL
chemotherapy	NULL
but	NULL
not	NULL
total-body	NULL
irradiation	NULL
.	NULL

At	NULL
the	NULL
time	NULL
of	NULL
the	NULL
study	NULL
,	NULL
patients	NULL
had	NULL
not	NULL
received	NULL
treatment	NULL
for	NULL
at	NULL
least	NULL
6	NULL
months	NULL
,	NULL
and	NULL
their	NULL
peripheral	NULL
counts	NULL
were	NULL
within	NULL
normal	NULL
ranges	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
APL	NULL
,	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
:	NULL
;	NULL
LCL	NULL
,	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
;	NULL
APC	NULL
,	NULL
antigen-presenting	NULL
cell	NULL
;	NULL
PBMC	NULL
,	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cell	NULL
;	NULL
LAK	NULL
,	NULL
lymphokine-activated	NULL
killer	NULL
:	NULL
IL	NULL
,	NULL
interleukin	NULL
;	NULL
HPLC	NULL
,	NULL
high-performance	NULL
liquid	NULL
chromatography	NULL
:	NULL
HS	NULL
,	NULL
human	NULL
serum	NULL
;	NULL
dThd	NULL
,	NULL
thymidine	NULL
;	NULL
PBL	NULL
,	NULL
peripheral	NULL
blood	NULL
lymphocyte	NULL
:	NULL
TNF-	NULL
«	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
;	NULL
GM-CSF	NULL
,	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
;	NULL
MAb	NULL
,	NULL
monoclonal	NULL
antibody	NULL
;	NULL
PHA	NULL
,	NULL
phytohe-magglutinin	NULL
;	NULL
TT	NULL
,	NULL
tetanus	NULL
toxoid	NULL
;	NULL
SI	NULL
.	NULL

stimulation	NULL
index	NULL
:	NULL
;	NULL
TCR	NULL
.	NULL

T-cell	NULL
receptor	NULL
.	NULL

Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1996	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

594	NULL
Immune	NULL
Recognition	NULL
of	NULL
the	NULL
pmI/RAR-	NULL
«	NULL
Protein	NULL
PBMCs	NULL
Peripheral	NULL
blood	NULL
was	NULL
obtained	NULL
from	NULL
two	NULL
healthy	NULL
donors	NULL
(	NULL
D.	NULL
E.	NULL
and	NULL
C.	NULL
H.	NULL
R.	NULL
)	NULL
and	NULL
four	NULL
APL	NULL
patients	NULL
in	NULL
remission	NULL
(	NULL
S.	NULL
R.	NULL
,	NULL
F.	NULL
R.	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
)	NULL
after	NULL
informed	NULL
consent	NULL
.	NULL

PBMCs	NULL
were	NULL
isolated	NULL
by	NULL
centrifugation	NULL
on	NULL
Ficoll	NULL
gradients	NULL
.	NULL

The	NULL
HLA	NULL
typing	NULL
was	NULL
as	NULL
follows	NULL
:	NULL
DE	NULL
(	NULL
A2,23	NULL
,	NULL
B49,35	NULL
,	NULL
DR1I1.13	NULL
)	NULL
,	NULL
CHR	NULL
(	NULL
A2,11	NULL
,	NULL
B35,60	NULL
,	NULL
DR1,4	NULL
)	NULL
,	NULL
SR	NULL
(	NULL
A1,24	NULL
,	NULL
B51	NULL
,	NULL
DR8,11	NULL
)	NULL
,	NULL
FR	NULL
(	NULL
A23	NULL
,	NULL
B49,51	NULL
,	NULL
DR4,1	NULL
1	NULL
)	NULL
,	NULL
MM	NULL
(	NULL
A23,10	NULL
,	NULL
B27,49	NULL
,	NULL
DR10,11	NULL
)	NULL
,	NULL
and	NULL
PG	NULL
(	NULL
A1,2	NULL
,	NULL
B15	NULL
,	NULL
DR1,11	NULL
)	NULL
.	NULL

Cell	NULL
Lines	NULL
Lymphoblastoid	NULL
cell	NULL
lines	NULL
(	NULL
DE.LCL	NULL
,	NULL
SR.LCL	NULL
,	NULL
FRLCL	NULL
,	NULL
MM.LCL	NULL
,	NULL
PG.LCL	NULL
,	NULL
and	NULL
CHR.LCL	NULL
)	NULL
were	NULL
prepared	NULL
from	NULL
PBMCs	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
6	NULL
)	NULL
.	NULL

LAK	NULL
cell	NULL
lines	NULL
were	NULL
prepared	NULL
by	NULL
culturing	NULL
PBMCs	NULL
with	NULL
recombinant	NULL
IL-2	NULL
(	NULL
10	NULL
units/ml	NULL
;	NULL
Euro-Cetus	NULL
BV	NULL
,	NULL
Amsterdam	NULL
,	NULL
the	NULL
Netherlands	NULL
)	NULL
.	NULL

The	NULL
Daudi	NULL
cell	NULL
line	NULL
was	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
(	NULL
Biowhittaker	NULL
,	NULL
Walkersville	NULL
,	NULL
MD	NULL
)	NULL
plus	NULL
10	NULL
%	NULL
FCS	NULL
(	NULL
Biological	NULL
Industries	NULL
,	NULL
Kibbutz	NULL
Beth	NULL
Haemek	NULL
,	NULL
Israel	NULL
)	NULL
.	NULL

FR.APL	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
bone	NULL
marrow	NULL
or	NULL
peripheral	NULL
blood	NULL
of	NULL
an	NULL
APL	NULL
patient	NULL
(	NULL
F.	NULL
R.	NULL
)	NULL
and	NULL
frozen	NULL
in	NULL
liquid	NULL
nitrogen	NULL
.	NULL

They	NULL
were	NULL
thawed	NULL
and	NULL
cultured	NULL
for	NULL
18	NULL
to	NULL
24	NULL
h	NULL
before	NULL
use	NULL
in	NULL
proliferation	NULL
or	NULL
cytotoxicity	NULL
tests	NULL
.	NULL

Peptides	NULL
The	NULL
following	NULL
peptides	NULL
were	NULL
used	NULL
:	NULL
BCR1/25	NULL
,	NULL
a	NULL
25-mer	NULL
(	NULL
NSNHVASGAGEAAIETQSSSSEEIV	NULL
)	NULL
peptide	NULL
,	NULL
and	NULL
a	NULL
pool	NULL
of	NULL
nine	NULL
different	NULL
9-mer	NULL
peptides	NULL
(	NULL
VASGAGEAA	NULL
,	NULL
ASGAGEAAL	NULL
,	NULL
SGAGEAAIE	NULL
,	NULL
GAGEAAIET	NULL
,	NULL
AGEAAIETQ	NULL
,	NULL
GEAAIETQS	NULL
,	NULL
EAAIETQSS	NULL
,	NULL
AAIETQSSS	NULL
,	NULL
and	NULL
AIETQSSSS	NULL
)	NULL
collectively	NULL
indicated	NULL
as	NULL
BCR1/9	NULL
.	NULL

They	NULL
encompass	NULL
the	NULL
BCR	NULL
!	NULL

1-type	NULL
fusion	NULL
region	NULL
of	NULL
the	NULL
pmI/RAR-	NULL
«	NULL
protein	NULL
(	NULL
4	NULL
)	NULL
.	NULL

The	NULL
peptides	NULL
were	NULL
synthesized	NULL
by	NULL
the	NULL
University	NULL
of	NULL
Wisconsin	NULL
Biotechnology	NULL
Center	NULL
(	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
or	NULL
American	NULL
Peptide	NULL
Company	NULL
(	NULL
Sunnyvale	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
purified	NULL
using	NULL
high-performance	NULL
liquid	NULL
chromatography	NULL
to	NULL
a	NULL
minimum	NULL
purity	NULL
of	NULL
95	NULL
%	NULL
.	NULL

Activation	NULL
of	NULL
Lymphocytes	NULL
The	NULL
protocol	NULL
described	NULL
by	NULL
Chen	NULL
et	NULL
al	NULL
.	NULL

(	NULL
7	NULL
)	NULL
was	NULL
followed	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
50	NULL
X	NULL
10°	NULL
fresh	NULL
PBMCs	NULL
(	NULL
10°	NULL
for	NULL
patient	NULL
P.	NULL
G.	NULL
and	NULL
donor	NULL
C.	NULL
H.	NULL
R.	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
a	NULL
humidified	NULL
atmosphere	NULL
at	NULL
37°C	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
with	NULL
20	NULL
jum	NULL
corresponding	NULL
peptides	NULL
at	NULL
5	NULL
X	NULL
10°	NULL
cells/ml	NULL
serum-free	NULL
RPMI	NULL
1640	NULL
medium	NULL
for	NULL
1	NULL
h.	NULL
Fresh	NULL
autologous	NULL
PBMCs	NULL
(	NULL
50	NULL
%	NULL
10°	NULL
cells	NULL
in	NULL
10	NULL
ml	NULL
RPMI	NULL
1640	NULL
medium	NULL
+	NULL
10	NULL
%	NULL
HS	NULL
)	NULL
were	NULL
added	NULL
to	NULL
each	NULL
APC	NULL
culture	NULL
in	NULL
culture	NULL
flasks	NULL
(	NULL
75	NULL
cm-*	NULL
)	NULL
.	NULL

The	NULL
flasks	NULL
were	NULL
incubated	NULL
upright	NULL
for	NULL
7	NULL
days	NULL
.	NULL

Primed	NULL
lymphocytes	NULL
were	NULL
then	NULL
harvested	NULL
and	NULL
restimulated	NULL
with	NULL
irradiated	NULL
(	NULL
3000	NULL
rad	NULL
)	NULL
autologous	NULL
PBMC-pulsed	NULL
peptides	NULL
(	NULL
20	NULL
jm	NULL
)	NULL
at	NULL
a	NULL
lymphocyte	NULL
:	NULL
APC	NULL
ratio	NULL
of	NULL
1:3	NULL
.	NULL

The	NULL
next	NULL
day	NULL
,	NULL
IL-2	NULL
(	NULL
10	NULL
units/ml	NULL
)	NULL
was	NULL
added	NULL
,	NULL
and	NULL
the	NULL
percentage	NULL
of	NULL
HS	NULL
was	NULL
increased	NULL
to	NULL
10	NULL
%	NULL
.	NULL

Five	NULL
days	NULL
later	NULL
,	NULL
one	NULL
half	NULL
of	NULL
the	NULL
medium	NULL
from	NULL
each	NULL
culture	NULL
was	NULL
replaced	NULL
with	NULL
RPMI	NULL
1640	NULL
+	NULL
10	NULL
%	NULL
HS	NULL
+	NULL
10	NULL
units/ml	NULL
IL-2	NULL
.	NULL

The	NULL
derived	NULL
T-cell	NULL
lines	NULL
were	NULL
left	NULL
in	NULL
culture	NULL
for	NULL
7	NULL
days	NULL
before	NULL
cloning	NULL
on	NULL
day	NULL
21	NULL
poststimulation	NULL
.	NULL

They	NULL
were	NULL
maintained	NULL
in	NULL
culture	NULL
by	NULL
periodic	NULL
stimulation	NULL
(	NULL
every	NULL
7-10	NULL
days	NULL
)	NULL
using	NULL
irradiated	NULL
(	NULL
8000	NULL
rad	NULL
)	NULL
autologous	NULL
LCL-pulsed	NULL
peptide	NULL
(	NULL
20	NULL
jm	NULL
)	NULL
and	NULL
IL-2	NULL
(	NULL
10	NULL
units/ml	NULL
)	NULL
.	NULL

To	NULL
test	NULL
for	NULL
proliferative	NULL
activity	NULL
of	NULL
the	NULL
derived	NULL
T-cell	NULL
lines	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
and	NULL
placed	NULL
in	NULL
U-bottomed	NULL
96-well	NULL
plates	NULL
(	NULL
5	NULL
x	NULL
10°	NULL
cells/well	NULL
)	NULL
.	NULL

They	NULL
were	NULL
stimulated	NULL
with	NULL
irradiated	NULL
(	NULL
8000	NULL
rad	NULL
)	NULL
autologous	NULL
LCLs	NULL
(	NULL
10°	NULL
cells/well	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
the	NULL
appropriate	NULL
peptides	NULL
.	NULL

LCL	NULL
cells	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
in	NULL
serum-free	NULL
RPMI	NULL
1640	NULL
medium	NULL
,	NULL
incubated	NULL
with	NULL
20	NULL
pum	NULL
peptides	NULL
as	NULL
indicated	NULL
above	NULL
,	NULL
and	NULL
then	NULL
irradiated	NULL
.	NULL

After	NULL
48	NULL
h	NULL
of	NULL
culture	NULL
,	NULL
the	NULL
plates	NULL
were	NULL
labeled	NULL
with	NULL
[	NULL
°H	NULL
}	NULL
dThd	NULL
,	NULL
further	NULL
cultured	NULL
for	NULL
18	NULL
h	NULL
,	NULL
harvested	NULL
,	NULL
and	NULL
counted	NULL
in	NULL
a	NULL
beta	NULL
counter	NULL
.	NULL

Generation	NULL
of	NULL
Lymphocyte	NULL
Clones	NULL
Primed	NULL
T-cell	NULL
lines	NULL
were	NULL
cloned	NULL
on	NULL
day	NULL
21	NULL
by	NULL
limiting	NULL
dilution	NULL
(	NULL
20	NULL
,	NULL
10	NULL
,	NULL
5	NULL
,	NULL
2	NULL
,	NULL
and	NULL
1	NULL
cell/well/200	NULL
pi	NULL
RPMI	NULL
1640	NULL
+	NULL
10	NULL
%	NULL
HS	NULL
)	NULL
in	NULL
96-well	NULL
U-bottomed	NULL
plates	NULL
.	NULL

Autologous	NULL
LCLs	NULL
,	NULL
PBLs	NULL
,	NULL
and	NULL
allogeneic	NULL
PBLs	NULL
(	NULL
25	NULL
x	NULL
10°	NULL
cells/well	NULL
)	NULL
were	NULL
used	NULL
as	NULL
a	NULL
feeder	NULL
layer	NULL
.	NULL

Autologous	NULL
PBLs	NULL
and	NULL
LCLs	NULL
were	NULL
incubated	NULL
separately	NULL
in	NULL
serum-free	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
cells/ml	NULL
)	NULL
with	NULL
20	NULL
pm	NULL
of	NULL
the	NULL
same	NULL
mixture	NULL
of	NULL
peptides	NULL
,	NULL
used	NULL
to	NULL
prime	NULL
lymphocytes	NULL
(	NULL
see	NULL
above	NULL
)	NULL
,	NULL
for	NULL
30	NULL
min	NULL
at	NULL
37°C	NULL
before	NULL
irradiation	NULL
(	NULL
3000	NULL
rad	NULL
for	NULL
PBL	NULL
s	NULL
and	NULL
8000	NULL
rad	NULL
for	NULL
LCL	NULL
cells	NULL
)	NULL
.	NULL

X-irradiated	NULL
(	NULL
3000	NULL
rad	NULL
)	NULL
allogeneic	NULL
PBLs	NULL
and	NULL
IL-2	NULL
(	NULL
50	NULL
units/ml	NULL
)	NULL
were	NULL
also	NULL
added	NULL
to	NULL
the	NULL
wells	NULL
.	NULL

The	NULL
plates	NULL
were	NULL
incubated	NULL
for	NULL
14	NULL
days	NULL
;	NULL
100	NULL
w	NULL
!	NULL

fresh	NULL
medium	NULL
and	NULL
50	NULL
units/ml	NULL
IL-2	NULL
were	NULL
replaced	NULL
in	NULL
each	NULL
well	NULL
every	NULL
3	NULL
days	NULL
.	NULL

Wells	NULL
with	NULL
positive	NULL
signs	NULL
of	NULL
growth	NULL
were	NULL
selected	NULL
for	NULL
expansion	NULL
(	NULL
see	NULL
'*Results	NULL
``	NULL
'	NULL
)	NULL
.	NULL

The	NULL
probability	NULL
of	NULL
clonality	NULL
for	NULL
each	NULL
well	NULL
containing	NULL
growth	NULL
was	NULL
calculated	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Growing	NULL
clones	NULL
were	NULL
transferred	NULL
to	NULL
96-well	NULL
flat-bottomed	NULL
plates	NULL
,	NULL
and	NULL
each	NULL
clone	NULL
was	NULL
stimulated	NULL
with	NULL
25	NULL
X	NULL
10°	NULL
irradiated	NULL
(	NULL
8000	NULL
rad	NULL
)	NULL
autologous	NULL
LCLs	NULL
pulsed	NULL
with	NULL
the	NULL
appropriate	NULL
peptides	NULL
(	NULL
20	NULL
wm	NULL
)	NULL
and	NULL
25	NULL
x	NULL
10°	NULL
(	NULL
3000	NULL
rad	NULL
)	NULL
irradiated	NULL
allogeneic	NULL
PBLs	NULL
.	NULL

IL-2	NULL
(	NULL
50	NULL
units/ml	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
wells	NULL
after	NULL
1	NULL
day	NULL
.	NULL

This	NULL
activation	NULL
cycle	NULL
was	NULL
repeated	NULL
after	NULL
7-10	NULL
days	NULL
of	NULL
culture	NULL
at	NULL
lymphocyte	NULL
:	NULL
autologous	NULL
LCL	NULL
:	NULL
allogeneic	NULL
PBL	NULL
ratios	NULL
of	NULL
1:1:1.	NULL
unless	NULL
otherwise	NULL
indicated	NULL
.	NULL

Screening	NULL
of	NULL
Clones	NULL
The	NULL
following	NULL
assays	NULL
were	NULL
carried	NULL
out	NULL
.	NULL

Proliferation	NULL
Assay	NULL
.	NULL

T-cell	NULL
clones	NULL
were	NULL
first	NULL
screened	NULL
for	NULL
proliferative	NULL
activity	NULL
28	NULL
days	NULL
after	NULL
cloning	NULL
.	NULL

Each	NULL
well	NULL
was	NULL
washed	NULL
off	NULL
to	NULL
remove	NULL
IL-2	NULL
and	NULL
split	NULL
into	NULL
three	NULL
.	NULL

The	NULL
first	NULL
one	NULL
was	NULL
expanded	NULL
for	NULL
further	NULL
culture	NULL
.	NULL

The	NULL
second	NULL
well	NULL
was	NULL
stimulated	NULL
with	NULL
irradiated	NULL
(	NULL
8000	NULL
rad	NULL
)	NULL
autologous	NULL
LCLs	NULL
(	NULL
10°	NULL
cells/well	NULL
)	NULL
pulsed	NULL
with	NULL
the	NULL
appropriate	NULL
peptides	NULL
(	NULL
20	NULL
pm	NULL
)	NULL
.	NULL

The	NULL
third	NULL
well	NULL
was	NULL
incubated	NULL
with	NULL
irradiated	NULL
LCLs	NULL
without	NULL
peptides	NULL
.	NULL

Cells	NULL
were	NULL
cultured	NULL
for	NULL
48	NULL
h	NULL
,	NULL
incubated	NULL
for	NULL
an	NULL
additional	NULL
18	NULL
h	NULL
with	NULL
[	NULL
°H	NULL
]	NULL
dThd	NULL
(	NULL
1	NULL
pCi/well	NULL
)	NULL
,	NULL
and	NULL
harvested	NULL
.	NULL

In	NULL
subsequent	NULL
experiments	NULL
,	NULL
the	NULL
incubation	NULL
time	NULL
was	NULL
reduced	NULL
to	NULL
24	NULL
h	NULL
(	NULL
see	NULL
``	NULL
Results	NULL
``	NULL
'	NULL
)	NULL
.	NULL

Cytotoxic	NULL
Assay	NULL
.	NULL

T-cell	NULL
clones	NULL
were	NULL
first	NULL
screened	NULL
for	NULL
cytotoxic	NULL
activity	NULL
6	NULL
weeks	NULL
after	NULL
cloning	NULL
:	NULL
;	NULL
one	NULL
third	NULL
of	NULL
the	NULL
cell	NULL
suspension	NULL
from	NULL
each	NULL
clone	NULL
was	NULL
admixed	NULL
with	NULL
°'Cr-labeled	NULL
autologous	NULL
LCL	NULL
s	NULL
(	NULL
10°	NULL
cell/well	NULL
)	NULL
as	NULL
a	NULL
control	NULL
,	NULL
and	NULL
the	NULL
other	NULL
third	NULL
was	NULL
incubated	NULL
with	NULL
LCLs	NULL
pulsed	NULL
with	NULL
peptide	NULL
(	NULL
20	NULL
pum	NULL
)	NULL
.	NULL

The	NULL
assay	NULL
was	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
6	NULL
)	NULL
.	NULL

The	NULL
incubation	NULL
time	NULL
was	NULL
4-6	NULL
h.	NULL
Spontaneous	NULL
release	NULL
never	NULL
exceeded	NULL
15	NULL
%	NULL
.	NULL

Anti-TNF-a	NULL
monoclonal	NULL
antibody	NULL
(	NULL
Farmitalia	NULL
,	NULL
Milan	NULL
,	NULL
Italy	NULL
)	NULL
and	NULL
TNF-a	NULL
(	NULL
EuroCetus	NULL
BV	NULL
)	NULL
were	NULL
used	NULL
in	NULL
some	NULL
assays	NULL
(	NULL
see	NULL
*'Results	NULL
``	NULL
'	NULL
)	NULL
.	NULL

Cytokine	NULL
Production	NULL
and	NULL
Detection	NULL
Assays	NULL
Cells	NULL
from	NULL
clone	NULL
C3/5	NULL
(	NULL
3	NULL
X	NULL
10°	NULL
cells	NULL
)	NULL
were	NULL
cultured	NULL
in	NULL
48-well	NULL
plates	NULL
(	NULL
1.5	NULL
X	NULL
10°	NULL
cells/ml	NULL
)	NULL
with	NULL
irradiated	NULL
(	NULL
8000	NULL
rad	NULL
)	NULL
autologous	NULL
DE.LCL	NULL
(	NULL
3	NULL
X	NULL
10°	NULL
cells	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1996	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

of	NULL
20	NULL
jum	NULL
peptide	NULL
(	NULL
25-mer	NULL
)	NULL
.	NULL

C3/5	NULL
cells	NULL
(	NULL
3	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
also	NULL
cultured	NULL
in	NULL
2	NULL
ml	NULL
RPMI	NULL
1640	NULL
+	NULL
10	NULL
%	NULL
HS	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
LCLs	NULL
.	NULL

The	NULL
supernatant	NULL
from	NULL
each	NULL
culture	NULL
(	NULL
2	NULL
ml	NULL
)	NULL
was	NULL
collected	NULL
by	NULL
centrifugation	NULL
after	NULL
1	NULL
and	NULL
2	NULL
days	NULL
.	NULL

immediately	NULL
frozen	NULL
in	NULL
liquid	NULL
nitrogen	NULL
,	NULL
and	NULL
stored	NULL
at	NULL
-80°C	NULL
until	NULL
used	NULL
.	NULL

The	NULL
cytokines	NULL
assayed	NULL
in	NULL
the	NULL
present	NULL
study	NULL
were	NULL
:	NULL
IL-2	NULL
,	NULL
IL-3	NULL
,	NULL
IL-4	NULL
,	NULL
IL-6	NULL
,	NULL
IFN-y	NULL
,	NULL
TNF-a	NULL
,	NULL
and	NULL
GM-CSF	NULL
.	NULL

IL-2	NULL
activity	NULL
was	NULL
measured	NULL
by	NULL
[	NULL
°H	NULL
]	NULL
dThd	NULL
uptake	NULL
of	NULL
IL-2-dependent	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
line	NULL
cells	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Ref	NULL
.	NULL

8	NULL
,	NULL
1	NULL
unit	NULL
biological	NULL
activity	NULL
was	NULL
referred	NULL
as	NULL
half-maximal	NULL
proliferation	NULL
of	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
line	NULL
cells	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
serial	NULL
dilutions	NULL
of	NULL
IL-2	NULL
or	NULL
supernatant	NULL
from	NULL
each	NULL
culture	NULL
were	NULL
incubated	NULL
in	NULL
200	NULL
ul	NULL
for	NULL
24	NULL
h	NULL
,	NULL
followed	NULL
by	NULL
an	NULL
overnight	NULL
pulse	NULL
of	NULL
1	NULL
p.Ci/well	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
dThd	NULL
.	NULL

IL-3	NULL
was	NULL
assayed	NULL
by	NULL
using	NULL
a	NULL
Quantikine	NULL
Human	NULL
IL-3	NULL
Immunoassay	NULL
(	NULL
Research	NULL
and	NULL
Diagnostic	NULL
Systems	NULL
,	NULL
Minneapolis	NULL
,	NULL
MN	NULL
)	NULL
with	NULL
a	NULL
detection	NULL
limit	NULL
of	NULL
30	NULL
pg/ml	NULL
.	NULL

IL-4	NULL
and	NULL
IFN-y	NULL
were	NULL
measured	NULL
using	NULL
the	NULL
sandwich	NULL
ELISA	NULL
as	NULL
described	NULL
in	NULL
detail	NULL
elsewhere	NULL
(	NULL
9	NULL
)	NULL
.	NULL

The	NULL
mouse	NULL
MAb	NULL
8F12	NULL
(	NULL
10	NULL
)	NULL
and	NULL
biotinylated	NULL
3H4	NULL
,	NULL
generously	NULL
provided	NULL
by	NULL
C.	NULL
H.	NULL
Heusser	NULL
(	NULL
Ciba-Geigy	NULL
Ltd.	NULL
,	NULL
Basel	NULL
,	NULL
Switzerland	NULL
)	NULL
.	NULL

were	NULL
used	NULL
for	NULL
IL-4	NULL
,	NULL
and	NULL
MAbs	NULL
43-11	NULL
and	NULL
biotinylated	NULL
45-15	NULL
,	NULL
kindly	NULL
supplied	NULL
by	NULL
S.	NULL
Alkan	NULL
(	NULL
Ciba-Geigy	NULL
Ltd.	NULL
)	NULL
.	NULL

were	NULL
used	NULL
for	NULL
IFN-y	NULL
.	NULL

The	NULL
sensitivities	NULL
of	NULL
the	NULL
IL-4	NULL
and	NULL
IFN-y	NULL
ELISA	NULL
were	NULL
30	NULL
and	NULL
40	NULL
pg/ml	NULL
.	NULL

respectively	NULL
.	NULL

IL-6	NULL
and	NULL
TNF-	NULL
were	NULL
analyzed	NULL
using	NULL
kits	NULL
from	NULL
Chromogenix	NULL
AB	NULL
(	NULL
Moilndal	NULL
,	NULL
Sweden	NULL
)	NULL
,	NULL
with	NULL
a	NULL
detection	NULL
limit	NULL
of	NULL
4	NULL
pg/ml	NULL
as	NULL
given	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

The	NULL
human	NULL
GM-CSF	NULL
was	NULL
assayed	NULL
using	NULL
Innotest	NULL
human	NULL
GM-CSF	NULL
from	NULL
Innogenetics	NULL
NV	NULL
(	NULL
Antwerp	NULL
,	NULL
Belgium	NULL
)	NULL
with	NULL
a	NULL
detection	NULL
limit	NULL
of	NULL
8	NULL
pg/ml	NULL
.	NULL

PHA	NULL
and	NULL
TT	NULL
Assays	NULL
PBLs	NULL
were	NULL
simultaneously	NULL
thawed	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
seeded	NULL
at	NULL
10°	NULL
cells/well	NULL
.	NULL

PHA	NULL
(	NULL
Murex	NULL
,	NULL
Temple	NULL
Hile	NULL
,	NULL
England	NULL
)	NULL
was	NULL
added	NULL
at	NULL
1	NULL
pg/ml	NULL
,	NULL
and	NULL
proliferation	NULL
was	NULL
assessed	NULL
as	NULL
[	NULL
°H	NULL
]	NULL
dThd	NULL
uptake	NULL
(	NULL
6-h	NULL
incubation	NULL
)	NULL
after	NULL
72	NULL
h.	NULL
For	NULL
proliferation	NULL
to	NULL
TT	NULL
(	NULL
10	NULL
pg/ml	NULL
;	NULL
Connaugh	NULL
Lab	NULL
)	NULL
,	NULL
2	NULL
X	NULL
10°	NULL
PBLs/well	NULL
were	NULL
cultured	NULL
for	NULL
6	NULL
days	NULL
and	NULL
labeled	NULL
with	NULL
[	NULL
°H	NULL
]	NULL
dThd	NULL
for	NULL
the	NULL
last	NULL
18	NULL
h	NULL
of	NULL
culture	NULL
.	NULL

Immunofluorescence	NULL
Assay	NULL
This	NULL
assay	NULL
was	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
11	NULL
)	NULL
.	NULL

The	NULL
MAbs	NULL
used	NULL
were	NULL
in	NULL
the	NULL
form	NULL
of	NULL
diluted	NULL
ascites	NULL
:	NULL
anti-CD3	NULL
,	NULL
anti-CD4	NULL
,	NULL
anti-CD8	NULL
,	NULL
anti-TCR-aB	NULL
,	NULL
anti-TCR-y8	NULL
,	NULL
anti-HLA	NULL
class	NULL
I	NULL
(	NULL
W6/32	NULL
)	NULL
,	NULL
and	NULL
anti-HLA	NULL
class	NULL
II	NULL
(	NULL
D1-12	NULL
)	NULL
.	NULL

Samples	NULL
were	NULL
analyzed	NULL
using	NULL
flow	NULL
cytometry	NULL
(	NULL
FACs	NULL
IV	NULL
:	NULL
Becton	NULL
Dickinson	NULL
,	NULL
Sunnyvale	NULL
,	NULL
CA	NULL
)	NULL
with	NULL
a	NULL
logarithmic	NULL
signal	NULL
amplification	NULL
.	NULL

Screening	NULL
for	NULL
HLA-binding	NULL
Motifs	NULL
A	NULL
list	NULL
including	NULL
the	NULL
binding	NULL
motifs	NULL
for	NULL
35	NULL
HLA	NULL
class	NULL
I	NULL
specificities	NULL
was	NULL
kindly	NULL
supplied	NULL
by	NULL
Dr.	NULL
H.	NULL
G.	NULL
Rammensee	NULL
(	NULL
Heidelberg	NULL
.	NULL

Germany	NULL
)	NULL
and	NULL
includes	NULL
the	NULL
following	NULL
specificities	NULL
:	NULL
Al	NULL
.	NULL

0201/5	NULL
,	NULL
3	NULL
,	NULL
11	NULL
,	NULL
24	NULL
,	NULL
31	NULL
.	NULL

33	NULL
,	NULL
68	NULL
;	NULL
B7	NULL
,	NULL
8	NULL
,	NULL
2702/5	NULL
,	NULL
3501/3	NULL
,	NULL
3701	NULL
,	NULL
3901/2	NULL
,	NULL
40	NULL
,	NULL
440273	NULL
,	NULL
5101/2/3	NULL
,	NULL
5201	NULL
,	NULL
53	NULL
,	NULL
58	NULL
,	NULL
60	NULL
.	NULL

61	NULL
,	NULL
62	NULL
,	NULL
78	NULL
;	NULL
Cw0301	NULL
,	NULL
0401	NULL
,	NULL
0602	NULL
,	NULL
0702	NULL
.	NULL

HLA	NULL
Stabilization	NULL
Assay	NULL
The	NULL
ability	NULL
of	NULL
peptides	NULL
to	NULL
bind	NULL
HLA	NULL
molecules	NULL
was	NULL
assessed	NULL
by	NULL
the	NULL
peptide-mediated	NULL
increase	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
HLA	NULL
expression	NULL
on	NULL
the	NULL
membrane	NULL
of	NULL
the	NULL
T2	NULL
(	NULL
12	NULL
)	NULL
.	NULL

L721.221	NULL
(	NULL
13	NULL
)	NULL
,	NULL
and	NULL
ST-EMO	NULL
(	NULL
14	NULL
)	NULL
cell	NULL
lines	NULL
.	NULL

Cw6	NULL
and	NULL
Cw0702	NULL
transfectants	NULL
of	NULL
T2	NULL
Clinical	NULL
Cancer	NULL
Research	NULL
595	NULL
20000	NULL
17500	NULL
~	NULL
15000	NULL
12500	NULL
10000	NULL
Mean	NULL
cpm	NULL
7500	NULL
4	NULL
so00o	NULL
2500	NULL
7	NULL
&	NULL
HUNT	NULL
NOD	NULL
PH	NULL
[	NULL
F	NULL
--	NULL
-	NULL
SR/9	NULL
SR/25	NULL
DE/9/25	NULL
Polyclonal	NULL
T	NULL
cell	NULL
lines	NULL
Fig	NULL
.	NULL

1	NULL
Proliferative	NULL
response	NULL
of	NULL
three	NULL
polyclonal	NULL
T-cell	NULL
lines	NULL
[	NULL
SR/9	NULL
,	NULL
SR/25	NULL
(	NULL
from	NULL
an	NULL
APL	NULL
patient	NULL
in	NULL
remission	NULL
)	NULL
,	NULL
and	NULL
DE/9/25	NULL
(	NULL
from	NULL
a	NULL
healthy	NULL
donor	NULL
)	NULL
]	NULL
against	NULL
BCR	NULL
1/9	NULL
,	NULL
BCR1/25	NULL
,	NULL
or	NULL
BCRI/9	NULL
+	NULL
BCR1/25	NULL
peptides	NULL
,	NULL
respectively	NULL
.	NULL

Each	NULL
T-cell	NULL
line	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
cells/well	NULL
)	NULL
was	NULL
cultured	NULL
for	NULL
48	NULL
h	NULL
with	NULL
irradiated	NULL
(	NULL
8000	NULL
rad	NULL
)	NULL
autologous	NULL
EBV-transformed	NULL
LCLs	NULL
(	NULL
10°	NULL
cells/well	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
§	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
(	NULL
)	NULL
of	NULL
the	NULL
corresponding	NULL
peptide	NULL
(	NULL
B	NULL
,	NULL
lymphocytes	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
+	NULL
10	NULL
%	NULL
HS	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
both	NULL
LCLs	NULL
and	NULL
peptides	NULL
)	NULL
.	NULL

They	NULL
were	NULL
incubated	NULL
for	NULL
an	NULL
additional	NULL
18	NULL
h	NULL
with	NULL
[	NULL
°H	NULL
]	NULL
dThd	NULL
and	NULL
harvested	NULL
.	NULL

LCLs	NULL
were	NULL
pulsed	NULL
with	NULL
peptides	NULL
in	NULL
serum-free	NULL
medium	NULL
for	NULL
30	NULL
min	NULL
before	NULL
irradiation	NULL
.	NULL

cpm	NULL
values	NULL
represent	NULL
the	NULL
mean	NULL
of	NULL
six	NULL
replicates	NULL
.	NULL

Bars	NULL
,	NULL
SD	NULL
.	NULL

and	NULL
L721,221	NULL
were	NULL
also	NULL
used	NULL
(	NULL
kindly	NULL
supplied	NULL
by	NULL
Dr.	NULL
D.	NULL
Schendel	NULL
,	NULL
Munich	NULL
Germany	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
in	NULL
serum-free	NULL
RPMI	NULL
1640	NULL
and	NULL
incubated	NULL
with	NULL
20-100	NULL
pg/ml	NULL
peptide	NULL
for	NULL
18	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

Expression	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
was	NULL
evaluated	NULL
by	NULL
indirect	NULL
immunofluorescence	NULL
with	NULL
W6/32	NULL
MAb	NULL
or	NULL
with	NULL
mono-specific	NULL
MAbs	NULL
GAP-A3	NULL
,	NULL
4E	NULL
(	NULL
anti-B/C	NULL
)	NULL
,	NULL
or	NULL
BB7.2	NULL
(	NULL
anti-A2	NULL
)	NULL
.	NULL

Positivity	NULL
was	NULL
defined	NULL
as	NULL
an	NULL
increase	NULL
by	NULL
at	NULL
least	NULL
50	NULL
%	NULL
in	NULL
the	NULL
median	NULL
channel	NULL
of	NULL
fluorescence	NULL
.	NULL

RESULTS	NULL
Polyclonal	NULL
T-Cell	NULL
Lines	NULL
.	NULL

-	NULL
The	NULL
results	NULL
for	NULL
the	NULL
proliferative	NULL
activity	NULL
of	NULL
T-cell	NULL
lines	NULL
,	NULL
obtained	NULL
from	NULL
an	NULL
APL	NULL
patient	NULL
in	NULL
remission	NULL
(	NULL
S.	NULL
R.	NULL
)	NULL
and	NULL
a	NULL
healthy	NULL
donor	NULL
(	NULL
D.	NULL
E.	NULL
)	NULL
,	NULL
are	NULL
presented	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

SR/9	NULL
and	NULL
SR/25	NULL
were	NULL
obtained	NULL
by	NULL
culture	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
BCR1/9	NULL
or	NULL
BCR1/25	NULL
;	NULL
DE/9/25	NULL
was	NULL
derived	NULL
from	NULL
cultures	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
both	NULL
BCR	NULL
1/9	NULL
and	NULL
BCR	NULL
1/25	NULL
peptides	NULL
.	NULL

SR	NULL
T-cell	NULL
lines	NULL
did	NULL
not	NULL
show	NULL
a	NULL
specific	NULL
proliferative	NULL
activity	NULL
against	NULL
autologous	NULL
peptide-pulsed	NULL
LCLs	NULL
.	NULL

A	NULL
low	NULL
but	NULL
reproducible	NULL
SI	NULL
(	NULL
SI	NULL
=	NULL
cpm	NULL
test	NULL
well/epm	NULL
control	NULL
well	NULL
)	NULL
of	NULL
2.2	NULL
was	NULL
obtained	NULL
for	NULL
the	NULL
DE/9/25	NULL
T-cell	NULL
line	NULL
.	NULL

These	NULL
lines	NULL
consisted	NULL
of	NULL
a	NULL
mixture	NULL
of	NULL
CD4	NULL
and	NULL
CD8-	NULL
«	NULL
/B	NULL
lymphocytes	NULL
.	NULL

No	NULL
specific	NULL
cytotoxic	NULL
activity	NULL
against	NULL
peptide-pulsed	NULL
LCLs	NULL
was	NULL
obtained	NULL
in	NULL
these	NULL
cell	NULL
lines	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

T-Cell	NULL
Clones	NULL
.	NULL

The	NULL
T-cell	NULL
lines	NULL
SR/9	NULL
,	NULL
SR/25	NULL
,	NULL
and	NULL
DE/	NULL
9/25	NULL
were	NULL
cloned	NULL
by	NULL
limiting	NULL
dilution	NULL
.	NULL

Two	NULL
hundred	NULL
fifteen	NULL
clones	NULL
(	NULL
with	NULL
a	NULL
clonal	NULL
probability	NULL
of	NULL
>	NULL
90	NULL
%	NULL
)	NULL
were	NULL
obtained	NULL
;	NULL
52	NULL
,	NULL
41	NULL
,	NULL
and	NULL
122	NULL
clones	NULL
were	NULL
generated	NULL
from	NULL
SR/9	NULL
,	NULL
SR/25	NULL
,	NULL
and	NULL
Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1996	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

596	NULL
Immune	NULL
Recognition	NULL
of	NULL
the	NULL
pmI/RAR-a	NULL
Protein	NULL
1090	NULL
ratio	NULL
5:1	NULL
go	NULL
70	NULL
J	NULL
ratio	NULL
50:1	NULL
19s	NULL
50	NULL
~	NULL
Specific	NULL
lys	NULL
30	NULL
7	NULL
%	NULL
20	NULL
7	NULL
Target	NULL
cells	NULL
Fig	NULL
.	NULL

2	NULL
Cytotoxic	NULL
activity	NULL
of	NULL
clone	NULL
C€3/5	NULL
(	NULL
E	NULL
,	NULL
effector	NULL
cells	NULL
)	NULL
against	NULL
autologous	NULL
DE.LCL	NULL
(	NULL
7	NULL
,	NULL
target	NULL
cells	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
BCR	NULL
1/9	NULL
(	NULL
B	NULL
)	NULL
and	NULL
BCR	NULL
1/25	NULL
(	NULL
C	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
A	NULL
)	NULL
of	NULL
peptide	NULL
.	NULL

LCLs	NULL
at	NULL
5	NULL
X	NULL
10°	NULL
cells/ml	NULL
were	NULL
incubated	NULL
with	NULL
*'Cr	NULL
for	NULL
90	NULL
min	NULL
with	NULL
or	NULL
without	NULL
peptides	NULL
(	NULL
20	NULL
jum	NULL
)	NULL
.	NULL

After	NULL
washing	NULL
,	NULL
the	NULL
peptides	NULL
were	NULL
readded	NULL
to	NULL
the	NULL
target	NULL
(	NULL
10°	NULL
cells/well	NULL
)	NULL
at	NULL
the	NULL
same	NULL
concentration	NULL
.	NULL

DE/9/25	NULL
,	NULL
respectively	NULL
.	NULL

Among	NULL
the	NULL
52	NULL
SR/9	NULL
and	NULL
the	NULL
41	NULL
SR/25	NULL
clones	NULL
tested	NULL
,	NULL
no	NULL
specific	NULL
cytotoxic	NULL
or	NULL
proliferative	NULL
activity	NULL
was	NULL
obtained	NULL
.	NULL

Proliferation	NULL
against	NULL
LCLs	NULL
pulsed	NULL
with	NULL
control	NULL
peptides	NULL
or	NULL
with	NULL
PBS	NULL
was	NULL
observed	NULL
in	NULL
several	NULL
clones	NULL
,	NULL
suggesting	NULL
autoreactivity	NULL
or	NULL
anti~EBV	NULL
reactivity	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Among	NULL
the	NULL
122	NULL
clones	NULL
obtained	NULL
from	NULL
the	NULL
DE/9/25	NULL
T-cell	NULL
line	NULL
,	NULL
59	NULL
were	NULL
selected	NULL
according	NULL
to	NULL
their	NULL
specific	NULL
proliferation	NULL
(	NULL
SI	NULL
>	NULL
2	NULL
)	NULL
or	NULL
cytotoxicity	NULL
(	NULL
specific	NULL
lysis	NULL
>	NULL
10	NULL
%	NULL
)	NULL
.	NULL

Fifty-five	NULL
clones	NULL
showed	NULL
specific	NULL
proliferation	NULL
to	NULL
the	NULL
peptide	NULL
pool	NULL
(	NULL
SI	NULL
ranged	NULL
from	NULL
2	NULL
to	NULL
16.47	NULL
)	NULL
with	NULL
four	NULL
clones	NULL
showing	NULL
specific	NULL
lysis	NULL
also	NULL
[	NULL
B9/5	NULL
(	NULL
17	NULL
%	NULL
)	NULL
,	NULL
C3/1	NULL
(	NULL
20	NULL
%	NULL
)	NULL
,	NULL
C35	NULL
(	NULL
19	NULL
%	NULL
)	NULL
,	NULL
and	NULL
C4/1	NULL
(	NULL
13	NULL
%	NULL
)	NULL
]	NULL
.	NULL

An	NULL
additional	NULL
four	NULL
clones	NULL
showed	NULL
specific	NULL
lysis	NULL
only	NULL
[	NULL
A4/5	NULL
(	NULL
19	NULL
%	NULL
)	NULL
,	NULL
E2/1	NULL
(	NULL
10.5	NULL
%	NULL
)	NULL
,	NULL
E3/1	NULL
(	NULL
23	NULL
%	NULL
)	NULL
,	NULL
and	NULL
F2/1	NULL
(	NULL
15	NULL
%	NULL
)	NULL
]	NULL
.	NULL

The	NULL
phenotype	NULL
of	NULL
these	NULL
clones	NULL
was	NULL
uniformly	NULL
CD3	NULL
,	NULL
CD4*	NULL
,	NULL
CD8~T	NULL
,	NULL
TCR-w/B*	NULL
,	NULL
and	NULL
TCR-y/6	NULL
~	NULL
.	NULL

One	NULL
clone	NULL
(	NULL
C3/5	NULL
)	NULL
,	NULL
which	NULL
showed	NULL
the	NULL
highest	NULL
and	NULL
the	NULL
most	NULL
stable	NULL
results	NULL
,	NULL
was	NULL
selected	NULL
for	NULL
further	NULL
analysis	NULL
.	NULL

In	NULL
subsequent	NULL
experiments	NULL
the	NULL
proliferative	NULL
and	NULL
cytotoxic	NULL
activity	NULL
of	NULL
the	NULL
C3/5	NULL
clone	NULL
against	NULL
BCR	NULL
1/25	NULL
and	NULL
BCR1/9	NULL
was	NULL
evaluated	NULL
.	NULL

BCR1/9	NULL
did	NULL
not	NULL
induce	NULL
specific	NULL
proliferation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
BCR	NULL
1/25	NULL
was	NULL
the	NULL
peptide	NULL
recognized	NULL
in	NULL
the	NULL
peptide	NULL
mixture	NULL
initially	NULL
used	NULL
for	NULL
stimulation	NULL
.	NULL

The	NULL
results	NULL
for	NULL
the	NULL
cytotoxic	NULL
activity	NULL
of	NULL
C3/5	NULL
against	NULL
autologous	NULL
LCLs	NULL
pulsed	NULL
separately	NULL
with	NULL
BCR1/25	NULL
and	NULL
BCR1/9	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

T-cell	NULL
clones	NULL
were	NULL
also	NULL
produced	NULL
,	NULL
with	NULL
the	NULL
same	NULL
stimulation	NULL
protocol	NULL
and	NULL
using	NULL
combined	NULL
or	NULL
separate	NULL
stimulation	NULL
with	NULL
BCR1/25	NULL
and	NULL
BCR1/9	NULL
,	NULL
from	NULL
three	NULL
additional	NULL
DR11*~	NULL
APL	NULL
patients	NULL
(	NULL
F.	NULL
R.	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
)	NULL
and	NULL
with	NULL
BCR	NULL
1/9	NULL
from	NULL
donors	NULL
C.	NULL
H.	NULL
R.	NULL
,	NULL
L.	NULL
R.	NULL
,	NULL
and	NULL
B.	NULL
C.	NULL
A	NULL
total	NULL
of	NULL
1015	NULL
clones	NULL
(	NULL
155	NULL
from	NULL
patient	NULL
F.	NULL
R.	NULL
,	NULL
106	NULL
from	NULL
patient	NULL
M.	NULL
M.	NULL
,	NULL
251	NULL
from	NULL
patient	NULL
P.	NULL
G.	NULL
,	NULL
Days	NULL
in	NULL
culture	NULL
Fig	NULL
.	NULL

3	NULL
Specific	NULL
cytokine	NULL
production	NULL
by	NULL
the	NULL
C3/5	NULL
clone	NULL
.	NULL

Cells	NULL
(	NULL
1.5	NULL
%	NULL
10°/ml	NULL
)	NULL
were	NULL
cultured	NULL
with	NULL
irradiated	NULL
(	NULL
8000	NULL
rad	NULL
)	NULL
autologous	NULL
DE.LCL	NULL
(	NULL
1.5	NULL
X	NULL
10°	NULL
cells/ml	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
@	NULL
and	NULL
¥	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
0	NULL
and	NULL
V	NULL
)	NULL
of	NULL
the	NULL
BCR1/25	NULL
peptide	NULL
(	NULL
20	NULL
jum	NULL
)	NULL
.	NULL

Supernatants	NULL
were	NULL
harvested	NULL
on	NULL
days	NULL
1	NULL
and	NULL
2	NULL
and	NULL
assayed	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
TNF-a	NULL
(	NULL
O	NULL
and	NULL
@	NULL
)	NULL
and	NULL
GM-CSF	NULL
(	NULL
V	NULL
and	NULL
¥	NULL
)	NULL
.	NULL

198	NULL
from	NULL
donor	NULL
C.	NULL
H.	NULL
R.	NULL
,	NULL
227	NULL
from	NULL
donor	NULL
L.	NULL
R.	NULL
,	NULL
and	NULL
188	NULL
from	NULL
donor	NULL
B.	NULL
C.	NULL
)	NULL
was	NULL
obtained	NULL
and	NULL
screened	NULL
.	NULL

No	NULL
specific	NULL
proliferative	NULL
or	NULL
cytotoxic	NULL
activity	NULL
was	NULL
observed	NULL
,	NULL
while	NULL
a	NULL
specific	NULL
response	NULL
was	NULL
obtained	NULL
from	NULL
donors	NULL
'	NULL
PBLs	NULL
(	NULL
all	NULL
being	NULL
HLA-A2*	NULL
)	NULL
in	NULL
response	NULL
to	NULL
the	NULL
influenza	NULL
peptide	NULL
GILGFVFTL	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Specific	NULL
Cytokine	NULL
Production	NULL
by	NULL
the	NULL
C3/5	NULL
Clone	NULL
in	NULL
Response	NULL
to	NULL
Autologous	NULL
Peptide-pulsed	NULL
LCLs	NULL
.	NULL

To	NULL
assess	NULL
cytokine	NULL
production	NULL
,	NULL
cells	NULL
from	NULL
the	NULL
C3/5	NULL
clone	NULL
were	NULL
stimulated	NULL
with	NULL
autologous	NULL
DE.LCL	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
the	NULL
BCR1/25	NULL
peptide	NULL
(	NULL
20	NULL
um	NULL
)	NULL
,	NULL
and	NULL
cytokine	NULL
production	NULL
was	NULL
measured	NULL
after	NULL
1	NULL
and	NULL
2	NULL
days	NULL
of	NULL
culture	NULL
.	NULL

IL-2	NULL
,	NULL
IL-3	NULL
,	NULL
IL-4	NULL
,	NULL
IL-6	NULL
,	NULL
IFN-y	NULL
,	NULL
TNF-a	NULL
,	NULL
and	NULL
GM-CSF	NULL
were	NULL
assayed	NULL
.	NULL

IL-2	NULL
,	NULL
IL-3	NULL
,	NULL
IL-4	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
IFN-y	NULL
levels	NULL
were	NULL
undetectable	NULL
or	NULL
below	NULL
the	NULL
detection	NULL
limit	NULL
of	NULL
the	NULL
assay	NULL
used	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

C3/5	NULL
cells	NULL
cultured	NULL
with	NULL
autologous	NULL
DE.LCL-puised	NULL
peptide	NULL
for	NULL
1	NULL
day	NULL
secreted	NULL
significant	NULL
amounts	NULL
of	NULL
TNF-a	NULL
(	NULL
933	NULL
,	NULL
1189	NULL
pg/ml	NULL
)	NULL
and	NULL
GM-CSF	NULL
(	NULL
3395	NULL
,	NULL
3301	NULL
pg/ml	NULL
)	NULL
in	NULL
two	NULL
separate	NULL
experiments	NULL
compared	NULL
with	NULL
those	NULL
stimulated	NULL
with	NULL
DE.LCL	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
peptide	NULL
(	NULL
26	NULL
pg/ml	NULL
or	NULL
below	NULL
the	NULL
detection	NULL
limit	NULL
for	NULL
TNF-	NULL
«	NULL
and	NULL
184	NULL
,	NULL
126	NULL
pg/ml	NULL
for	NULL
GM-CSF	NULL
)	NULL
.	NULL

TNF-a	NULL
and	NULL
GM-CSF	NULL
production	NULL
peaked	NULL
at	NULL
day	NULL
1	NULL
and	NULL
remained	NULL
stable	NULL
at	NULL
day	NULL
2	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
TNF-	NULL
«	NULL
produced	NULL
by	NULL
the	NULL
C3/5	NULL
clone	NULL
could	NULL
be	NULL
involved	NULL
in	NULL
its	NULL
cytolytic	NULL
activity	NULL
,	NULL
TNF-a	NULL
and	NULL
anti-TNF-e	NULL
MAb	NULL
were	NULL
used	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
anti-	NULL
TNF-a	NULL
at	NULL
different	NULL
concentrations	NULL
0.1	NULL
,	NULL
1	NULL
,	NULL
and	NULL
10	NULL
pg/ml	NULL
to	NULL
the	NULL
target	NULL
cells	NULL
DE.LCL	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
the	NULL
peptide	NULL
,	NULL
did	NULL
not	NULL
inhibit	NULL
the	NULL
cytolytic	NULL
activity	NULL
exerted	NULL
by	NULL
the	NULL
€3/5	NULL
clone	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

The	NULL
antibody	NULL
was	NULL
instead	NULL
active	NULL
in	NULL
inhibiting	NULL
the	NULL
cytotoxic	NULL
activity	NULL
of	NULL
TNF-a	NULL
against	NULL
the	NULL
TNF-o-sensitive	NULL
WEHI	NULL
164	NULL
cell	NULL
line	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

TNF-a	NULL
,	NULL
at	NULL
1-1000	NULL
units/ml	NULL
,	NULL
had	NULL
no	NULL
cytolytic	NULL
activity	NULL
on	NULL
DE.LCL	NULL
cells	NULL
when	NULL
added	NULL
for	NULL
the	NULL
same	NULL
Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1996	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

Clinical	NULL
Cancer	NULL
Research	NULL
597	NULL
60	NULL
50	NULL
1	NULL
480	NULL
30	NULL
20	NULL
4	NULL
]	NULL
®	NULL
%	NULL
Specific	NULL
lysis	NULL
10	NULL
{	NULL
3:1	NULL
6:1	NULL
121	NULL
}	NULL
1	NULL
24	NULL
}	NULL
1	NULL
ratio	NULL
Fig	NULL
.	NULL

4	NULL
Effect	NULL
of	NULL
MAb	NULL
directed	NULL
against	NULL
TNF-	NULL
«	NULL
produced	NULL
by	NULL
the	NULL
C3/5	NULL
clone	NULL
on	NULL
the	NULL
cytotoxic	NULL
activity	NULL
.	NULL

Cells	NULL
from	NULL
the	NULL
C3/5	NULL
clone	NULL
were	NULL
challenged	NULL
with	NULL
autologous	NULL
DE.LCL	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
peptide	NULL
(	NULL
0	NULL
)	NULL
and	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
20	NULL
um	NULL
BCR1/25	NULL
peptide	NULL
(	NULL
@	NULL
)	NULL
.	NULL

Anti-TNF-a	NULL
at	NULL
0.1	NULL
pg/ml	NULL
(	NULL
V	NULL
)	NULL
,	NULL
1	NULL
pg/ml	NULL
(	NULL
¥	NULL
)	NULL
,	NULL
and	NULL
10	NULL
pg/ml	NULL
(	NULL
C	NULL
)	NULL
)	NULL
was	NULL
mixed	NULL
with	NULL
LCL-pulsed	NULL
peptide	NULL
(	NULL
BCR1/25	NULL
)	NULL
before	NULL
the	NULL
effector	NULL
cells	NULL
were	NULL
added	NULL
.	NULL

duration	NULL
of	NULL
the	NULL
cytotoxic	NULL
assay	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
results	NULL
indicate	NULL
that	NULL
cytotoxic	NULL
activity	NULL
and	NULL
TNF-a	NULL
release	NULL
probably	NULL
represent	NULL
two	NULL
separate	NULL
functions	NULL
in	NULL
clone	NULL
€3/5	NULL
,	NULL
although	NULL
both	NULL
are	NULL
specifically	NULL
induced	NULL
by	NULL
BCR1/25	NULL
.	NULL

Reactivity	NULL
of	NULL
C3/5	NULL
toward	NULL
HLA-DR11	NULL
Allogeneic	NULL
APLs	NULL
,	NULL
LCLs	NULL
,	NULL
and	NULL
PBLs	NULL
.	NULL

-	NULL
Five	NULL
allogeneic	NULL
LCLs	NULL
[	NULL
SR	NULL
,	NULL
FR	NULL
,	NULL
MM	NULL
,	NULL
PG	NULL
(	NULL
sharing	NULL
DR11	NULL
with	NULL
DE	NULL
and	NULL
obtained	NULL
from	NULL
APL	NULL
patients	NULL
)	NULL
and	NULL
CHR	NULL
(	NULL
DR11T	NULL
)	NULL
]	NULL
were	NULL
subjected	NULL
to	NULL
a	NULL
cytotoxic	NULL
test	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
BCR	NULL
1/25	NULL
(	NULL
20	NULL
um	NULL
)	NULL
at	NULL
different	NULL
E	NULL
:	NULL
T	NULL
ratios	NULL
.	NULL

The	NULL
results	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

The	NULL
C3/5	NULL
clone	NULL
specifically	NULL
lysed	NULL
DR11-matched	NULL
SR	NULL
,	NULL
FR	NULL
,	NULL
and	NULL
MM	NULL
[	NULL
and	NULL
PG	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
]	NULL
LCLs	NULL
pulsed	NULL
with	NULL
BCR1/25	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
autologous	NULL
DE.LCL	NULL
.	NULL

CHR	NULL
cells	NULL
failed	NULL
to	NULL
present	NULL
the	NULL
peptide	NULL
to	NULL
the	NULL
C3/5	NULL
clone	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
the	NULL
C3/5	NULL
clone	NULL
to	NULL
proliferate	NULL
to	NULL
the	NULL
autologous	NULL
DE.LCL	NULL
and	NULL
HLA-DR11-matched	NULL
SR	NULL
,	NULL
FR	NULL
,	NULL
MM	NULL
,	NULL
and	NULL
PG.LCL	NULL
pulsed	NULL
with	NULL
different	NULL
peptide	NULL
concentrations	NULL
was	NULL
also	NULL
investi-gated	NULL
.	NULL

A	NULL
preliminary	NULL
experiment	NULL
was	NULL
carried	NULL
out	NULL
to	NULL
determine	NULL
the	NULL
optimal	NULL
stimulation	NULL
period	NULL
giving	NULL
the	NULL
highest	NULL
proliferative	NULL
activity	NULL
of	NULL
clone	NULL
C3/5	NULL
at	NULL
this	NULL
stage	NULL
of	NULL
culture	NULL
.	NULL

Cells	NULL
were	NULL
cultured	NULL
for	NULL
24	NULL
,	NULL
48	NULL
,	NULL
and	NULL
72	NULL
h	NULL
with	NULL
autologous	NULL
irradiated	NULL
(	NULL
8000	NULL
rad	NULL
)	NULL
DE.LCL	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
2	NULL
and	NULL
20	NULL
m	NULL
)	NULL
or	NULL
absence	NULL
of	NULL
the	NULL
BCR1/25	NULL
peptide	NULL
,	NULL
incubated	NULL
for	NULL
an	NULL
additional	NULL
18	NULL
h	NULL
with	NULL
[	NULL
°H	NULL
]	NULL
JdThd	NULL
,	NULL
and	NULL
harvested	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

64	NULL
,	NULL
the	NULL
24	NULL
h-	NULL
time	NULL
point	NULL
gave	NULL
the	NULL
highest	NULL
cpm	NULL
count	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
using	NULL
the	NULL
?	NULL

test	NULL
analysis	NULL
)	NULL
.	NULL

The	NULL
proliferative	NULL
activity	NULL
of	NULL
the	NULL
C3/5	NULL
clone	NULL
against	NULL
autologous	NULL
and	NULL
allogeneic	NULL
LCL-pulsed	NULL
peptide	NULL
(	NULL
0	NULL
,	NULL
5	NULL
,	NULL
20	NULL
,	NULL
and	NULL
50	NULL
M	NULL
)	NULL
was	NULL
subsequently	NULL
studied	NULL
at	NULL
the	NULL
24-h	NULL
time	NULL
point	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

All	NULL
DR11*	NULL
peptide-pulsed	NULL
LCLs	NULL
stimulated	NULL
the	NULL
C3/5	NULL
clone	NULL
in	NULL
a	NULL
dose-dependent	NULL
fashion	NULL
(	NULL
PG.PBL	NULL
induced	NULL
an	NULL
uptake	NULL
of	NULL
38,500	NULL
90	NULL
}	NULL
so	NULL
-	NULL
m-	NULL
~	NULL
E	NULL
To	NULL
-	NULL
_/	NULL
©	NULL
_	NULL
/	NULL
_3	NULL
50	NULL
-	NULL
//o	NULL
GA	NULL
40	NULL
-|	NULL
®	NULL
___	NULL
-A	NULL
a	NULL
v	NULL
QSG	NULL
``	NULL
v_///	NULL
”	NULL
—	NULL
(	NULL
0	NULL
/	NULL
r	NULL
20	NULL
{	NULL
V7	NULL
.	NULL

A	NULL
.	NULL

10	NULL
~-	NULL
,	NULL
|	NULL
by-	NULL
_|	NULL
3:1	NULL
6:1	NULL
12	NULL
}	NULL
1	NULL
24	NULL
;	NULL
1	NULL
Effector	NULL
:	NULL
Target	NULL
ratio	NULL
Fig	NULL
.	NULL

5	NULL
Cytotoxic	NULL
activity	NULL
of	NULL
clone	NULL
€3/5	NULL
against	NULL
autologous	NULL
DE.LCL	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
O	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
@	NULL
)	NULL
of	NULL
peptide	NULL
,	NULL
and	NULL
allogeneic	NULL
SR.LCL	NULL
(	NULL
V	NULL
and	NULL
¥	NULL
)	NULL
,	NULL
FR.LCL	NULL
(	NULL
0	NULL
and	NULL
fI	NULL
)	NULL
,	NULL
MM.LCL	NULL
(	NULL
A	NULL
and	NULL
A	NULL
)	NULL
,	NULL
and	NULL
CHR.LCL	NULL
(	NULL
©	NULL
and	NULL
#	NULL
)	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
@	NULL
,	NULL
MBB	NULL
,	NULL
A	NULL
,	NULL
and	NULL
#	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
0	NULL
,	NULL
.	NULL

A	NULL
,	NULL
and	NULL
©	NULL
)	NULL
of	NULL
20	NULL
um	NULL
BCR1/25	NULL
.	NULL

+	NULL
2,300	NULL
cpm	NULL
)	NULL
.	NULL

Although	NULL
some	NULL
discrepancies	NULL
between	NULL
proliferation	NULL
and	NULL
cytotoxicity	NULL
were	NULL
observed	NULL
(	NULL
SR	NULL
and	NULL
MM.LCL	NULL
induced	NULL
a	NULL
good	NULL
proliferative	NULL
response	NULL
but	NULL
produced	NULL
low	NULL
levels	NULL
of	NULL
cytotoxicity	NULL
,	NULL
while	NULL
FR.LCL	NULL
induced	NULL
little	NULL
proliferation	NULL
but	NULL
was	NULL
very	NULL
efficiently	NULL
lysed	NULL
by	NULL
€3/5	NULL
)	NULL
,	NULL
all	NULL
four	NULL
APL	NULL
patients	NULL
'	NULL
LCLs	NULL
were	NULL
able	NULL
to	NULL
present	NULL
peptide	NULL
BCR1/25	NULL
to	NULL
C3/5	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
LCLs	NULL
derived	NULL
from	NULL
APL	NULL
patients	NULL
to	NULL
present	NULL
peptide	NULL
BCR1/25	NULL
to	NULL
C3/5	NULL
suggests	NULL
that	NULL
the	NULL
failure	NULL
in	NULL
raising	NULL
anti-pmI/RAR-	NULL
«	NULL
clones	NULL
from	NULL
the	NULL
four	NULL
APL	NULL
patients	NULL
was	NULL
probably	NULL
not	NULL
due	NULL
to	NULL
a	NULL
defect	NULL
in	NULL
antigen	NULL
presentation	NULL
capability	NULL
.	NULL

To	NULL
further	NULL
investigate	NULL
this	NULL
point	NULL
,	NULL
this	NULL
experiment	NULL
was	NULL
replicated	NULL
using	NULL
patients	NULL
'	NULL
PBLs	NULL
(	NULL
instead	NULL
of	NULL
LCLs	NULL
)	NULL
as	NULL
APCs	NULL
.	NULL

The	NULL
results	NULL
are	NULL
presented	NULL
in	NULL
Table	NULL
1	NULL
,	NULL
and	NULL
confirm	NULL
that	NULL
the	NULL
antigen	NULL
presentation	NULL
capability	NULL
in	NULL
the	NULL
APL	NULL
patients	NULL
studied	NULL
was	NULL
grossly	NULL
intact	NULL
.	NULL

Since	NULL
the	NULL
C3/5	NULL
clone	NULL
was	NULL
specifically	NULL
able	NULL
to	NULL
lyse	NULL
FR.LCL	NULL
cells	NULL
pulsed	NULL
with	NULL
the	NULL
BCR1/25	NULL
peptide	NULL
in	NULL
a	NULL
HLA	NULL
class	NULL
II	NULL
(	NULL
DR11	NULL
)	NULL
restriction	NULL
fashion	NULL
,	NULL
we	NULL
further	NULL
tested	NULL
whether	NULL
this	NULL
clone	NULL
could	NULL
exert	NULL
a	NULL
cytotoxic	NULL
activity	NULL
against	NULL
FR.APL	NULL
cells	NULL
.	NULL

Because	NULL
APL	NULL
cells	NULL
are	NULL
usually	NULL
DR~	NULL
,	NULL
FR.blasts	NULL
(	NULL
285	NULL
%	NULL
leukemic	NULL
cells	NULL
)	NULL
were	NULL
also	NULL
cultured	NULL
with	NULL
IFN-y	NULL
(	NULL
a	NULL
cytokine	NULL
known	NULL
to	NULL
induce	NULL
or	NULL
enhance	NULL
the	NULL
expression	NULL
of	NULL
HLA	NULL
class	NULL
II	NULL
molecules	NULL
)	NULL
before	NULL
being	NULL
used	NULL
.	NULL

The	NULL
results	NULL
are	NULL
present	NULL
in	NULL
Fig	NULL
.	NULL

7	NULL
.	NULL

C3/5	NULL
cells	NULL
did	NULL
not	NULL
lyse	NULL
FR.APL	NULL
blasts	NULL
and	NULL
the	NULL
culture	NULL
of	NULL
FR.APL	NULL
cells	NULL
with	NULL
IFN-y	NULL
(	NULL
10°	NULL
units/ml	NULL
)	NULL
for	NULL
48	NULL
h	NULL
before	NULL
the	NULL
experiment	NULL
did	NULL
not	NULL
enhance	NULL
the	NULL
cytolytic	NULL
activity	NULL
.	NULL

This	NULL
was	NULL
possibly	NULL
due	NULL
to	NULL
the	NULL
failure	NULL
of	NULL
IFN-y	NULL
to	NULL
induce	NULL
HLA	NULL
class	NULL
II	NULL
molecules	NULL
on	NULL
FR.APL	NULL
blasts	NULL
as	NULL
assayed	NULL
by	NULL
immunofluorescence	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

FR.APL	NULL
cells	NULL
were	NULL
also	NULL
unable	NULL
to	NULL
present	NULL
peptide	NULL
BCR1/25	NULL
even	NULL
after	NULL
IFN-y	NULL
pre-incubation	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
the	NULL
interaction	NULL
of	NULL
C3/5	NULL
cells	NULL
with	NULL
peptide-pulsed	NULL
FR.LCL	NULL
could	NULL
kill	NULL
the	NULL
APL	NULL
blasts	NULL
by	NULL
a	NULL
bystander	NULL
Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1996	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

598	NULL
Immune	NULL
Recognition	NULL
of	NULL
the	NULL
pmIl/RAR-	NULL
«	NULL
Protein	NULL
22500	NULL
20000	NULL
17500	NULL
1589080	NULL
12500	NULL
190000	NULL
Mean	NULL
cpm	NULL
7500	NULL
58908	NULL
2500	NULL
Time	NULL
in	NULL
culture	NULL
(	NULL
hours	NULL
)	NULL
45000	NULL
40009	NULL
35000	NULL
30000	NULL
25000	NULL
20000	NULL
Mean	NULL
cpm	NULL
150800	NULL
10000	NULL
5009	NULL
Stimulators	NULL
(	NULL
LCL	NULL
)	NULL
Fig	NULL
.	NULL

6	NULL
-	NULL
Proliferative	NULL
response	NULL
of	NULL
the	NULL
C3/5	NULL
clone	NULL
against	NULL
the	NULL
BCR1/25	NULL
peptide	NULL
.	NULL

In	NULL
A	NULL
,	NULL
the	NULL
C3/5	NULL
clone	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
cells/well	NULL
)	NULL
was	NULL
cultured	NULL
for	NULL
24	NULL
,	NULL
48	NULL
,	NULL
and	NULL
72	NULL
h	NULL
with	NULL
irradiated	NULL
(	NULL
8000	NULL
rad	NULL
)	NULL
autologous	NULL
DE.LCL	NULL
(	NULL
10°	NULL
cells/well	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
©	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
2	NULL
pM	NULL
(	NULL
&	NULL
)	NULL
and	NULL
20	NULL
um	NULL
(	NULL
M	NULL
)	NULL
of	NULL
peptide	NULL
BCR	NULL
1/25	NULL
(	NULL
[	NULL
,	NULL
lymphocytes	NULL
cultured	NULL
in	NULL
medium	NULL
alone	NULL
)	NULL
.	NULL

In	NULL
8	NULL
,	NULL
the	NULL
C3/5	NULL
clone	NULL
(	NULL
5	NULL
X	NULL
10	NULL
``	NULL
cells/well	NULL
)	NULL
was	NULL
cultured	NULL
for	NULL
24	NULL
h	NULL
with	NULL
irradiated	NULL
(	NULL
8000	NULL
rad	NULL
)	NULL
autologous	NULL
DE.LCL	NULL
or	NULL
allogeneic	NULL
SR.LCL	NULL
,	NULL
FR.LCL	NULL
,	NULL
and	NULL
MM.LCL	NULL
(	NULL
10°	NULL
cells/well	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
5	NULL
uM	NULL
(	NULL
8	NULL
)	NULL
,	NULL
20	NULL
jm	NULL
(	NULL
@	NULL
)	NULL
,	NULL
and	NULL
50	NULL
pm	NULL
(	NULL
MB	NULL
)	NULL
or	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
[	NULL
I	NULL
]	NULL
)	NULL
of	NULL
BCR1/25	NULL
peptide	NULL
.	NULL

LCLs	NULL
at	NULL
5	NULL
X	NULL
10°	NULL
cells/ml	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
peptide	NULL
for	NULL
30	NULL
min	NULL
before	NULL
irradiation	NULL
,	NULL
cultured	NULL
for	NULL
an	NULL
additional	NULL
18	NULL
h	NULL
with	NULL
[	NULL
°H	NULL
}	NULL
dThd	NULL
,	NULL
and	NULL
harvested	NULL
.	NULL

cpm	NULL
values	NULL
represent	NULL
the	NULL
means	NULL
of	NULL
three	NULL
replicates	NULL
.	NULL

Bars	NULL
,	NULL
SD	NULL
.	NULL

effect	NULL
,	NULL
peptide-puilsed	NULL
FR.LCL	NULL
cells	NULL
were	NULL
admixed	NULL
with	NULL
labeled	NULL
FR.APL	NULL
cells	NULL
at	NULL
a	NULL
1:1	NULL
ratio	NULL
before	NULL
incubation	NULL
with	NULL
the	NULL
C3/5	NULL
effector	NULL
clone	NULL
.	NULL

Even	NULL
under	NULL
these	NULL
conditions	NULL
,	NULL
C3/5	NULL
cells	NULL
were	NULL
unable	NULL
to	NULL
lyse	NULL
FR.APL	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

FR.APL	NULL
cells	NULL
proved	NULL
otherwise	NULL
sensitive	NULL
to	NULL
lysis	NULL
as	NULL
evidenced	NULL
by	NULL
the	NULL
ability	NULL
of	NULL
LAK	NULL
cells	NULL
to	NULL
nonspecifically	NULL
lyse	NULL
these	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

Identical	NULL
results	NULL
were	NULL
obtained	NULL
using	NULL
leukemic	NULL
cells	NULL
from	NULL
patient	NULL
P.	NULL
G.	NULL
and	NULL
increasing	NULL
the	NULL
incubation	NULL
time	NULL
to	NULL
6	NULL
h	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Table	NULL
1	NULL
-	NULL
Antigen	NULL
presentation	NULL
capability	NULL
of	NULL
APL	NULL
patients	NULL
'	NULL
PBL	NULL
``	NULL
Type	NULL
of	NULL
APCs	NULL
+	NULL
BCR	NULL
1/25	NULL
-	NULL
BCR	NULL
1/25	NULL
DELCL	NULL
21.305	NULL
+	NULL
162	NULL
3,161	NULL
+	NULL
320	NULL
DE.PBL	NULL
18,083	NULL
+	NULL
2,607	NULL
6,067	NULL
+	NULL
360	NULL
SR.PBL	NULL
16,556	NULL
+	NULL
3,995	NULL
5,638	NULL
+	NULL
941	NULL
FR.PBL	NULL
18,650	NULL
+	NULL
113	NULL
4,645	NULL
+	NULL
847	NULL
MM.PBL	NULL
15,178	NULL
+	NULL
3,659	NULL
4,210	NULL
+	NULL
266	NULL
PG.PBL	NULL
18,025	NULL
+	NULL
1,856	NULL
3,541	NULL
+	NULL
188	NULL
``	NULL
C3/5	NULL
cells	NULL
(	NULL
50,000/well	NULL
)	NULL
were	NULL
cocultured	NULL
with	NULL
10°	NULL
irradiated	NULL
APCs	NULL
incubated	NULL
with	NULL
BCR	NULL
1/25	NULL
(	NULL
25	NULL
pm	NULL
)	NULL
or	NULL
PBS	NULL
.	NULL

Plates	NULL
were	NULL
cultured	NULL
for	NULL
48	NULL
h	NULL
,	NULL
labeled	NULL
with	NULL
[	NULL
°H	NULL
]	NULL
dThd	NULL
for	NULL
additional	NULL
18	NULL
h	NULL
,	NULL
and	NULL
harvested	NULL
.	NULL

Values	NULL
represent	NULL
the	NULL
mean	NULL
X	NULL
SD	NULL
cpm	NULL
obtained	NULL
in	NULL
three	NULL
replicates	NULL
.	NULL

C/5	NULL
cells	NULL
incubated	NULL
in	NULL
medium	NULL
alone	NULL
incorporated	NULL
195	NULL
+	NULL
70	NULL
cpm	NULL
;	NULL
irradiated	NULL
APCs	NULL
incorporated	NULL
419-841	NULL
cpm	NULL
.	NULL

60	NULL
49	NULL
38	NULL
20	NULL
{	NULL
%	NULL
Specific	NULL
lysis	NULL
‘	NULL
\	NULL
e	NULL
Effector	NULL
:	NULL
Target	NULL
ratio	NULL
Fig	NULL
.	NULL

7	NULL
Cytotoxic	NULL
activity	NULL
of	NULL
clone	NULL
C3/5	NULL
against	NULL
allogeneic	NULL
FR.APL	NULL
blasts	NULL
before	NULL
and	NULL
after	NULL
incubation	NULL
with	NULL
IFN-y	NULL
(	NULL
10°	NULL
units/ml	NULL
,	NULL
48	NULL
h	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
@	NULL
,	NULL
MB	NULL
,	NULL
¥	NULL
,	NULL
and	NULL
A	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
©	NULL
,	NULL
O	NULL
,	NULL
O	NULL
,	NULL
V	NULL
,	NULL
and	NULL
A	NULL
)	NULL
of	NULL
the	NULL
BCR1/25	NULL
peptide	NULL
.	NULL

The	NULL
target	NULL
cells	NULL
used	NULL
were	NULL
:	NULL
FR.LCL	NULL
(	NULL
O	NULL
and	NULL
@	NULL
)	NULL
,	NULL
FR.APL	NULL
(	NULL
V	NULL
and	NULL
¥	NULL
)	NULL
,	NULL
FR.APL	NULL
+	NULL
FR.LCL	NULL
(	NULL
C	NULL
)	NULL
and	NULL
MW	NULL
)	NULL
,	NULL
FR.APL	NULL
+	NULL
IFN-y	NULL
(	NULL
A	NULL
and	NULL
A	NULL
)	NULL
,	NULL
and	NULL
LAK	NULL
+	NULL
FR.APL	NULL
(	NULL
0	NULL
)	NULL
.	NULL

PHA	NULL
and	NULL
TT	NULL
Responses	NULL
of	NULL
Patients	NULL
'	NULL
PBLs	NULL
.	NULL

Because	NULL
of	NULL
the	NULL
negative	NULL
results	NULL
obtained	NULL
with	NULL
lymphocytes	NULL
from	NULL
APL	NULL
patients	NULL
,	NULL
a	NULL
PHA	NULL
response	NULL
assay	NULL
was	NULL
performed	NULL
to	NULL
test	NULL
the	NULL
T-cell	NULL
response	NULL
in	NULL
these	NULL
patients	NULL
.	NULL

Results	NULL
are	NULL
presented	NULL
in	NULL
Table	NULL
2	NULL
and	NULL
show	NULL
that	NULL
,	NULL
compared	NULL
to	NULL
PBLs	NULL
from	NULL
two	NULL
normal	NULL
donors	NULL
(	NULL
D.	NULL
E.	NULL
and	NULL
C.	NULL
H.	NULL
R.	NULL
)	NULL
,	NULL
patients	NULL
'	NULL
PBLs	NULL
showed	NULL
a	NULL
dramatically	NULL
reduced	NULL
response	NULL
.	NULL

These	NULL
results	NULL
were	NULL
surprising	NULL
to	NULL
us	NULL
,	NULL
since	NULL
all	NULL
patients	NULL
were	NULL
studied	NULL
while	NULL
in	NULL
remission	NULL
and	NULL
off	NULL
treatment	NULL
for	NULL
>	NULL
6	NULL
months	NULL
(	NULL
F.	NULL
R.	NULL
was	NULL
in	NULL
complete	NULL
remission	NULL
and	NULL
off	NULL
therapy	NULL
for	NULL
>	NULL
2	NULL
years	NULL
)	NULL
.	NULL

Comparable	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
response	NULL
to	NULL
a	NULL
specific	NULL
antigen	NULL
(	NULL
TT	NULL
)	NULL
was	NULL
evaluated	NULL
.	NULL

Six-day	NULL
proliferative	NULL
responses	NULL
to	NULL
TT	NULL
averaged	NULL
293,959	NULL
+	NULL
42,793	NULL
(	NULL
SD	NULL
)	NULL
cpm	NULL
in	NULL
three	NULL
donors	NULL
(	NULL
including	NULL
D.	NULL
E.	NULL
and	NULL
C.	NULL
H.	NULL
R.	NULL
)	NULL
and	NULL
49,602	NULL
*+	NULL
15,047	NULL
cpm	NULL
in	NULL
the	NULL
patient	NULL
group	NULL
(	NULL
P	NULL
=	NULL
0.002	NULL
)	NULL
.	NULL

Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1996	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

Clinical	NULL
Cancer	NULL
Research	NULL
599	NULL
Table	NULL
2	NULL
PHA	NULL
response	NULL
in	NULL
four	NULL
APL	NULL
patients	NULL
and	NULL
two	NULL
healthy	NULL
donors	NULL
Type	NULL
of	NULL
cells	NULL
With	NULL
PHA	NULL
Without	NULL
PHA	NULL
DEPBL	NULL
20,528	NULL
+	NULL
2613	NULL
107	NULL
*	NULL
87	NULL
SR.PBL	NULL
3,281	NULL
+	NULL
48	NULL
228	NULL
+	NULL
97	NULL
FR.PBL	NULL
8,381	NULL
+	NULL
476	NULL
171	NULL
*	NULL
56	NULL
MM.PBL	NULL
1,930	NULL
*	NULL
100	NULL
214	NULL
+	NULL
59	NULL
PG.PBL	NULL
9,150	NULL
+	NULL
1,987	NULL
326	NULL
+	NULL
83	NULL
CHR.PBL	NULL
26,547	NULL
+	NULL
2,438	NULL
335	NULL
+	NULL
101	NULL
``	NULL
Cells	NULL
were	NULL
thawed	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
seeded	NULL
at	NULL
10°	NULL
cells/well	NULL
(	NULL
see	NULL
*'Patients	NULL
and	NULL
Methods	NULL
``	NULL
``	NULL
)	NULL
.	NULL

Values	NULL
represent	NULL
mean	NULL
cpm	NULL
*	NULL
SD	NULL
from	NULL
six	NULL
replicates	NULL
.	NULL

Screening	NULL
of	NULL
the	NULL
pml/RAR-	NULL
«	NULL
Fusion	NULL
Region	NULL
for	NULL
HLA	NULL
Class	NULL
I-binding	NULL
Motifs	NULL
.	NULL

Although	NULL
donor	NULL
lymphocytes	NULL
can	NULL
recognize	NULL
pmI/RAR-a	NULL
«	NULL
peptides	NULL
in	NULL
a	NULL
DR-restricted	NULL
fashion	NULL
,	NULL
attempts	NULL
at	NULL
generating	NULL
class	NULL
T-restricted	NULL
CTLs	NULL
in	NULL
two	NULL
donors	NULL
(	NULL
and	NULL
in	NULL
two	NULL
patients	NULL
)	NULL
failed	NULL
.	NULL

We	NULL
recently	NULL
obtained	NULL
the	NULL
binding	NULL
motifs	NULL
for	NULL
the	NULL
35	NULL
most	NULL
frequent	NULL
class	NULL
I	NULL
alleles	NULL
and	NULL
matched	NULL
these	NULL
motifs	NULL
against	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
pmI/RAR-	NULL
«	NULL
fusion	NULL
region	NULL
.	NULL

No	NULL
good	NULL
matching	NULL
was	NULL
identified	NULL
,	NULL
``	NULL
suggesting	NULL
the	NULL
lack	NULL
of	NULL
binding	NULL
motifs	NULL
for	NULL
the	NULL
class	NULL
I	NULL
HLA	NULL
molecules	NULL
most	NULL
frequently	NULL
encountered	NULL
in	NULL
the	NULL
general	NULL
population	NULL
.	NULL

To	NULL
provide	NULL
partial	NULL
confirmation	NULL
to	NULL
these	NULL
negative	NULL
findings	NULL
,	NULL
BCRI1/9	NULL
peptides	NULL
were	NULL
separately	NULL
used	NULL
in	NULL
HLA	NULL
stabilization	NULL
experiments	NULL
.	NULL

Different	NULL
cell	NULL
lines	NULL
(	NULL
see	NULL
*'Patients	NULL
and	NULL
Methods	NULL
``	NULL
``	NULL
)	NULL
were	NULL
used	NULL
,	NULL
enabling	NULL
us	NULL
to	NULL
assess	NULL
binding	NULL
to	NULL
HLA-A2,3	NULL
,	NULL
B5101,63	NULL
,	NULL
and	NULL
Cw0701,0702	NULL
.	NULL

Appropriate	NULL
positive	NULL
control	NULL
peptides	NULL
(	NULL
natural	NULL
ligands	NULL
)	NULL
were	NULL
included	NULL
and	NULL
induced	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
mean	NULL
channel	NULL
of	NULL
fluorescence	NULL
of	NULL
150	NULL
%	NULL
(	NULL
A0201	NULL
)	NULL
,	NULL
500	NULL
%	NULL
(	NULL
A0301	NULL
)	NULL
,	NULL
and	NULL
269	NULL
%	NULL
(	NULL
Cw0702	NULL
)	NULL
.	NULL

All	NULL
BCR1/9	NULL
peptides	NULL
induced	NULL
increments	NULL
of	NULL
<	NULL
20	NULL
%	NULL
(	NULL
or	NULL
no	NULL
increase	NULL
at	NULL
all	NULL
)	NULL
over	NULL
values	NULL
obtained	NULL
with	NULL
control	NULL
unrelated	NULL
peptides	NULL
.	NULL

DISCUSSION	NULL
The	NULL
data	NULL
presented	NULL
here	NULL
demonstrate	NULL
specific	NULL
proliferation	NULL
,	NULL
cytotoxicity	NULL
,	NULL
and	NULL
cytokine	NULL
production	NULL
by	NULL
HLA-DR11*	NULL
donor	NULL
CD4	NULL
T-cell	NULL
clones	NULL
upon	NULL
challenge	NULL
with	NULL
HLA-DR1L	NULL
LCLs	NULL
or	NULL
PBLs	NULL
pulsed	NULL
with	NULL
the	NULL
BCR1/25	NULL
peptide	NULL
;	NULL
no	NULL
BCR1/9	NULL
peptide-specific	NULL
CD8/HLA	NULL
class	NULL
I-restricted	NULL
response	NULL
could	NULL
be	NULL
generated	NULL
in	NULL
both	NULL
donors	NULL
and	NULL
patients	NULL
.	NULL

We	NULL
also	NULL
showed	NULL
that	NULL
these	NULL
clones	NULL
could	NULL
not	NULL
be	NULL
obtained	NULL
in	NULL
four	NULL
HLA-DR	NULL
11	NULL
*	NULL
APL	NULL
patients	NULL
,	NULL
and	NULL
that	NULL
APL	NULL
blasts	NULL
from	NULL
DR11	NULL
patients	NULL
were	NULL
not	NULL
recognized	NULL
by	NULL
a	NULL
DRI	NULL
1-restricted	NULL
CD4	NULL
T-cell	NULL
clone	NULL
and	NULL
were	NULL
unable	NULL
to	NULL
present	NULL
peptide	NULL
BCR1/25	NULL
.	NULL

These	NULL
results	NULL
raise	NULL
several	NULL
questions	NULL
regarding	NULL
the	NULL
possible	NULL
recognition	NULL
of	NULL
the	NULL
APL-specific	NULL
pmI/RAR-a	NULL
molecule	NULL
by	NULL
T	NULL
cells	NULL
.	NULL

On	NULL
one	NULL
side	NULL
,	NULL
our	NULL
results	NULL
confirm	NULL
previous	NULL
findings	NULL
that	NULL
donor	NULL
T	NULL
cells	NULL
can	NULL
recognize	NULL
a	NULL
peptide	NULL
encompassing	NULL
the	NULL
fusion	NULL
region	NULL
of	NULL
the	NULL
pmI/RAR-	NULL
«	NULL
molecule	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Previous	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
cellular	NULL
processing	NULL
of	NULL
the	NULL
pmI/RAR-	NULL
«	NULL
protein	NULL
can	NULL
produce	NULL
peptides	NULL
that	NULL
stimulate	NULL
anti-BCR1/25	NULL
clones	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
show	NULL
that	NULL
BCR1/25-specific	NULL
T-cell	NULL
clones	NULL
can	NULL
also	NULL
exert	NULL
a	NULL
specific	NULL
cytotoxic	NULL
activity	NULL
and	NULL
release	NULL
cytokines	NULL
upon	NULL
stimulation	NULL
with	NULL
the	NULL
peptide	NULL
.	NULL

We	NULL
also	NULL
present	NULL
evidence	NULL
that	NULL
cytotoxic	NULL
activity	NULL
and	NULL
TNF-a	NULL
release	NULL
by	NULL
these	NULL
clones	NULL
are	NULL
separate	NULL
functions	NULL
,	NULL
although	NULL
both	NULL
seem	NULL
to	NULL
be	NULL
BCR1/25	NULL
specific	NULL
.	NULL

*	NULL
C.	NULL
Gambacorti-Passerini	NULL
,	NULL
unpublished	NULL
results	NULL
.	NULL

Finally	NULL
,	NULL
LCLs	NULL
and	NULL
PBLs	NULL
derived	NULL
from	NULL
APL	NULL
patients	NULL
expressing	NULL
the	NULL
relevant	NULL
restriction	NULL
element	NULL
(	NULL
HLA-DR	NULL
11	NULL
)	NULL
are	NULL
able	NULL
to	NULL
present	NULL
BCR1/25	NULL
similar	NULL
to	NULL
autologous	NULL
LCLs	NULL
.	NULL

On	NULL
the	NULL
other	NULL
side	NULL
,	NULL
two	NULL
different	NULL
sets	NULL
of	NULL
data	NULL
have	NULL
to	NULL
be	NULL
considered	NULL
.	NULL

First	NULL
,	NULL
repeated	NULL
attempts	NULL
at	NULL
generating	NULL
anti-BCR1/25	NULL
T-cell	NULL
clones	NULL
in	NULL
four	NULL
DR11+*	NULL
APL	NULL
patients	NULL
were	NULL
not	NULL
successful	NULL
.	NULL

These	NULL
results	NULL
can	NULL
not	NULL
be	NULL
attributed	NULL
to	NULL
an	NULL
insufficient	NULL
antigen-presenting	NULL
capability	NULL
in	NULL
these	NULL
patients	NULL
,	NULL
since	NULL
their	NULL
LCLs	NULL
and	NULL
PBL	NULL
s	NULL
induced	NULL
proliferation	NULL
and	NULL
cytotoxicity	NULL
in	NULL
the	NULL
€3/5	NULL
clone	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
BCR1/25	NULL
similar	NULL
to	NULL
autologous	NULL
LCLs	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
frequency	NULL
and/or	NULL
the	NULL
responsiveness	NULL
of	NULL
anti-BCR1/25	NULL
lymphocytes	NULL
was	NULL
particularly	NULL
low	NULL
in	NULL
these	NULL
patients	NULL
,	NULL
even	NULL
if	NULL
PBLs	NULL
were	NULL
recovered	NULL
when	NULL
the	NULL
patients	NULL
were	NULL
in	NULL
remission	NULL
with	NULL
normal	NULL
peripheral	NULL
blood	NULL
counts	NULL
and	NULL
T-cell	NULL
subsets	NULL
values	NULL
.	NULL

The	NULL
results	NULL
of	NULL
the	NULL
PHA	NULL
and	NULL
TT	NULL
response	NULL
assays	NULL
strongly	NULL
support	NULL
this	NULL
conclusion	NULL
and	NULL
indicate	NULL
that	NULL
a	NULL
generalized	NULL
impairment	NULL
of	NULL
the	NULL
cellular	NULL
immune	NULL
system	NULL
,	NULL
already	NULL
reported	NULL
in	NULL
cancer	NULL
patients	NULL
(	NULL
15	NULL
)	NULL
,	NULL
can	NULL
be	NULL
present	NULL
even	NULL
during	NULL
long-term	NULL
remissions	NULL
.	NULL

The	NULL
molecular	NULL
analysis	NULL
of	NULL
the	NULL
observed	NULL
hyporespon-siveness	NULL
is	NULL
presently	NULL
under	NULL
investigation	NULL
in	NULL
our	NULL
laboratory	NULL
.	NULL

The	NULL
possible	NULL
deletion	NULL
or	NULL
suppression	NULL
of	NULL
anti-pmIl/RAR-	NULL
«	NULL
-specific	NULL
T-cell	NULL
clones	NULL
by	NULL
APL	NULL
cells	NULL
is	NULL
another	NULL
possibility	NULL
that	NULL
deserves	NULL
further	NULL
investigation	NULL
as	NULL
well	NULL
as	NULL
ways	NULL
to	NULL
increase	NULL
the	NULL
in	NULL
vivo	NULL
frequency	NULL
of	NULL
anti-pmI/RAR-a	NULL
precursors	NULL
in	NULL
APL	NULL
patients	NULL
.	NULL

The	NULL
failure	NULL
to	NULL
generate	NULL
anti-BCR1/25-specific	NULL
clones	NULL
in	NULL
APL	NULL
patients	NULL
represents	NULL
the	NULL
most	NULL
relevant	NULL
problem	NULL
to	NULL
be	NULL
solved	NULL
before	NULL
therapeutic	NULL
approaches	NULL
can	NULL
be	NULL
considered	NULL
.	NULL

Second	NULL
,	NULL
in	NULL
both	NULL
APL	NULL
patients	NULL
and	NULL
healthy	NULL
donors	NULL
we	NULL
were	NULL
unable	NULL
to	NULL
raise	NULL
CD8	NULL
,	NULL
HLA	NULL
class-I	NULL
restricted	NULL
T-cell	NULL
clones	NULL
.	NULL

This	NULL
is	NULL
of	NULL
particular	NULL
importance	NULL
given	NULL
the	NULL
usual	NULL
and	NULL
strong	NULL
suppression	NULL
of	NULL
the	NULL
DR	NULL
gene	NULL
expression	NULL
in	NULL
APL	NULL
cells	NULL
.	NULL

Although	NULL
our	NULL
strategy	NULL
of	NULL
pulsing	NULL
APCs	NULL
with	NULL
short	NULL
peptides	NULL
could	NULL
not	NULL
have	NULL
been	NULL
successful	NULL
for	NULL
technical	NULL
reasons	NULL
,	NULL
it	NULL
produced	NULL
positive	NULL
results	NULL
in	NULL
other	NULL
systems	NULL
(	NULL
16	NULL
)	NULL
and	NULL
against	NULL
known	NULL
immunogenic	NULL
peptides	NULL
.	NULL

It	NULL
has	NULL
been	NULL
demonstrated	NULL
that	NULL
inhibitory	NULL
peptides	NULL
competitively	NULL
block	NULL
the	NULL
binding	NULL
to	NULL
HLA	NULL
molecules	NULL
of	NULL
stimulatory	NULL
peptides	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Since	NULL
a	NULL
mixture	NULL
of	NULL
9-mer	NULL
peptides	NULL
was	NULL
used	NULL
in	NULL
our	NULL
experiments	NULL
,	NULL
peptide	NULL
cross-inhibition	NULL
can	NULL
not	NULL
be	NULL
excluded	NULL
.	NULL

The	NULL
use	NULL
of	NULL
different	NULL
stimulation	NULL
protocols	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
using	NULL
pmI/RAR-	NULL
«	NULL
-transfected	NULL
cells	NULL
)	NULL
or	NULL
APCs	NULL
(	NULL
like	NULL
dendritic	NULL
cells	NULL
)	NULL
could	NULL
produce	NULL
positive	NULL
results	NULL
.	NULL

These	NULL
results	NULL
can	NULL
also	NULL
be	NULL
explained	NULL
by	NULL
the	NULL
observed	NULL
lack	NULL
of	NULL
effective	NULL
binding	NULL
motifs	NULL
for	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
in	NULL
the	NULL
pmI/RAR-	NULL
«	NULL
junction	NULL
.	NULL

A	NULL
recent	NULL
article	NULL
by	NULL
Bocchia	NULL
et	NULL
al	NULL
.	NULL

(	NULL
18	NULL
)	NULL
,	NULL
analyzing	NULL
HLA	NULL
binding	NULL
to	NULL
two	NULL
pmIl/RAR-	NULL
«	NULL
peptides	NULL
,	NULL
is	NULL
consistent	NULL
with	NULL
such	NULL
an	NULL
hypothesis	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
in	NULL
APL	NULL
,	NULL
the	NULL
pmI/RAR-	NULL
«	NULL
protein	NULL
is	NULL
recognized	NULL
by	NULL
T	NULL
lymphocytes	NULL
,	NULL
but	NULL
only	NULL
when	NULL
presented	NULL
by	NULL
a	NULL
restriction	NULL
element	NULL
(	NULL
HLA-DR11	NULL
)	NULL
that	NULL
is	NULL
not	NULL
present	NULL
on	NULL
the	NULL
APL	NULL
cells	NULL
themselves	NULL
.	NULL

The	NULL
recognition	NULL
of	NULL
putative	NULL
DR*	NULL
APL	NULL
stem	NULL
cells	NULL
in	NULL
the	NULL
form	NULL
of	NULL
colony-forming	NULL
units	NULL
could	NULL
still	NULL
be	NULL
possible	NULL
.	NULL

However	NULL
,	NULL
the	NULL
existence	NULL
of	NULL
these	NULL
cells	NULL
has	NULL
yet	NULL
to	NULL
be	NULL
demonstrated	NULL
(	NULL
19	NULL
)	NULL
,	NULL
and	NULL
true	NULL
APL	NULL
colonies	NULL
are	NULL
difficult	NULL
to	NULL
obtain	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Alter-natively	NULL
,	NULL
the	NULL
induction	NULL
of	NULL
DR	NULL
molecules	NULL
on	NULL
APL	NULL
cells	NULL
could	NULL
permit	NULL
an	NULL
efficient	NULL
immune	NULL
recognition	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
lack	NULL
of	NULL
expression	NULL
of	NULL
DR	NULL
molecules	NULL
by	NULL
APL	NULL
cells	NULL
and	NULL
the	NULL
resulting	NULL
inability	NULL
of	NULL
DR11*	NULL
APL	NULL
cells	NULL
to	NULL
present	NULL
pml/	NULL
RAR-a	NULL
peptides	NULL
could	NULL
also	NULL
be	NULL
reflected	NULL
by	NULL
the	NULL
lack	NULL
of	NULL
clinical	NULL
significance	NULL
of	NULL
DR11	NULL
expression	NULL
in	NULL
APL	NULL
patients	NULL
undergoing	NULL
bone	NULL
marrow	NULL
transplantation	NULL
.	NULL

In	NULL
collaboration	NULL
with	NULL
the	NULL
Interna-	NULL
Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1996	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

600	NULL
Immune	NULL
Recognition	NULL
of	NULL
the	NULL
pmI/RAR-a	NULL
Protein	NULL
tional	NULL
Bone	NULL
Marrow	NULL
Transplant	NULL
Registry	NULL
,	NULL
an	NULL
analysis	NULL
was	NULL
conducted	NULL
in	NULL
189	NULL
APL	NULL
patients	NULL
in	NULL
first	NULL
remission	NULL
who	NULL
underwent	NULL
an	NULL
allogeneic	NULL
related	NULL
bone	NULL
marrow	NULL
transplant	NULL
.	NULL

The	NULL
patients	NULL
were	NULL
grouped	NULL
into	NULL
HLA-DR11*	NULL
(	NULL
n	NULL
=	NULL
44	NULL
)	NULL
and	NULL
HLA-DR11I~	NULL
(	NULL
n	NULL
=	NULL
145	NULL
)	NULL
.	NULL

No	NULL
significant	NULL
difference	NULL
in	NULL
survival	NULL
or	NULL
disease-free	NULL
survival	NULL
was	NULL
evident	NULL
between	NULL
the	NULL
two	NULL
groups	NULL
.	NULL

Also	NULL
,	NULL
the	NULL
proportion	NULL
of	NULL
DR11	NULL
patients	NULL
(	NULL
23	NULL
%	NULL
)	NULL
does	NULL
not	NULL
differ	NULL
significantly	NULL
from	NULL
that	NULL
seen	NULL
in	NULL
the	NULL
general	NULL
population	NULL
.	NULL
``	NULL

In	NULL
case	NULL
the	NULL
pmIl/RAR-	NULL
«	NULL
junction	NULL
could	NULL
not	NULL
be	NULL
presented	NULL
by	NULL
the	NULL
HLA	NULL
class	NULL
I	NULL
molecule	NULL
,	NULL
then	NULL
the	NULL
only	NULL
chance	NULL
that	NULL
this	NULL
fusion	NULL
protein	NULL
can	NULL
be	NULL
recognized	NULL
in	NULL
APL	NULL
cells	NULL
by	NULL
T	NULL
lymphocytes	NULL
resides	NULL
in	NULL
the	NULL
restoration	NULL
of	NULL
DR	NULL
expression	NULL
through	NULL
pharmacological	NULL
(	NULL
21	NULL
)	NULL
or	NULL
genetic	NULL
manipulation	NULL
,	NULL
or	NULL
in	NULL
the	NULL
targeting	NULL
of	NULL
the	NULL
still	NULL
hypothetical	NULL
DR	NULL
*	NULL
APL	NULL
stem	NULL
cells	NULL
.	NULL

Our	NULL
studies	NULL
demonstrate	NULL
that	NULL
the	NULL
BCR1/25	NULL
peptide	NULL
corresponding	NULL
to	NULL
the	NULL
fusion	NULL
region	NULL
of	NULL
the	NULL
pmI/RAR-a	NULL
«	NULL
protein	NULL
present	NULL
in	NULL
APL	NULL
cells	NULL
can	NULL
be	NULL
specifically	NULL
recognized	NULL
by	NULL
donor	NULL
(	NULL
but	NULL
not	NULL
by	NULL
patient	NULL
)	NULL
CD4	NULL
T	NULL
cells	NULL
in	NULL
a	NULL
HLA	NULL
class	NULL
II	NULL
(	NULL
DR11	NULL
)	NULL
-restricted	NULL
fash-ion	NULL
;	NULL
CD8/HLA	NULL
class	NULL
I-restricted	NULL
T	NULL
cells	NULL
were	NULL
not	NULL
generated	NULL
,	NULL
possibly	NULL
due	NULL
to	NULL
the	NULL
lack	NULL
of	NULL
HLA-binding	NULL
motifs	NULL
in	NULL
the	NULL
pml/	NULL
RAR-a	NULL
fusion	NULL
region	NULL
.	NULL

Finally	NULL
,	NULL
APL	NULL
blasts	NULL
were	NULL
not	NULL
lysed	NULL
by	NULL
anti-pmI/RAR-	NULL
«	NULL
cytotoxic	NULL
T	NULL
cell	NULL
clones	NULL
due	NULL
to	NULL
the	NULL
lack	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
DR11	NULL
molecule	NULL
by	NULL
the	NULL
APL	NULL
blasts	NULL
studied	NULL
.	NULL

Further	NULL
immunotherapeutic	NULL
approaches	NULL
to	NULL
APL	NULL
will	NULL
need	NULL
to	NULL
overcome	NULL
the	NULL
two	NULL
main	NULL
problems	NULL
encountered	NULL
in	NULL
this	NULL
study	NULL
:	NULL
the	NULL
lack	NULL
of	NULL
DR	NULL
expression	NULL
in	NULL
APL	NULL
cells	NULL
(	NULL
20	NULL
)	NULL
and	NULL
the	NULL
poor	NULL
immune	NULL
status	NULL
of	NULL
APL	NULL
patients	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Dr.	NULL
H.	NULL
G.	NULL
Rammensee	NULL
for	NULL
providing	NULL
the	NULL
HLA-binding	NULL
motifs	NULL
and	NULL
for	NULL
critical	NULL
reading	NULL
of	NULL
the	NULL
manuscript	NULL
,	NULL
and	NULL
Dr.	NULL
M.	NULL
M.	NULL
Horowitz	NULL
,	NULL
Dr.	NULL
P.	NULL
A.	NULL
Rowlings	NULL
,	NULL
and	NULL
Dr.	NULL
M.	NULL
M.	NULL
Bortin	NULL
(	NULL
International	NULL
Bone	NULL
Marrow	NULL
Transplant	NULL
Registry	NULL
,	NULL
Milwaukee	NULL
,	NULL
WI	NULL
)	NULL
for	NULL
providing	NULL
survival	NULL
data	NULL
analysis	NULL
on	NULL
transplanted	NULL
APL	NULL
patients	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
the	NULL
Antony	NULL
Nolan	NULL
Foundation	NULL
(	NULL
London	NULL
,	NULL
England	NULL
)	NULL
which	NULL
kindly	NULL
provided	NULL
the	NULL
CHR	NULL
cells	NULL
,	NULL
Dr.	NULL
M.	NULL
T.	NULL
IMleni	NULL
for	NULL
HLA	NULL
class	NULL
I	NULL
typing	NULL
,	NULL
Dr.	NULL
F.	NULL
Poli	NULL
(	NULL
Ospedale	NULL
Maggiore	NULL
,	NULL
Milan	NULL
,	NULL
Italy	NULL
)	NULL
for	NULL
DR	NULL
typing	NULL
,	NULL
and	NULL
T.	NULL
Blesken	NULL
for	NULL
technical	NULL
assistance	NULL
in	NULL
the	NULL
cytokine	NULL
detection	NULL
assays	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Rowley	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Golomb	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
and	NULL
Dougherty	NULL
,	NULL
C.	NULL
15/17	NULL
transloca-tion	NULL
,	NULL
a	NULL
consistent	NULL
chromosomal	NULL
change	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Lancet	NULL
,	NULL
7	NULL
:	NULL
549-550	NULL
,	NULL
1977	NULL
.	NULL

2.	NULL
dethe	NULL
,	NULL
H.	NULL
,	NULL
Chomienne	NULL
,	NULL
C.	NULL
,	NULL
Lanotte	NULL
,	NULL
M.	NULL
,	NULL
Degos	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Dejean	NULL
,	NULL
A	NULL
.	NULL

The	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
translocation	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukaemia	NULL
fuses	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
gene	NULL
to	NULL
a	NULL
novel	NULL
transcribed	NULL
locus	NULL
,	NULL
Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
347	NULL
:	NULL
558-561	NULL
,	NULL
1990	NULL
.	NULL

3	NULL
.	NULL

Borrow	NULL
,	NULL
J.	NULL
,	NULL
Goddard	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Sheer	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Solomon	NULL
,	NULL
E.	NULL
Molecular	NULL
analysis	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
breakpoint	NULL
cluster	NULL
region	NULL
on	NULL
chromosome	NULL
17	NULL
.	NULL

Science	NULL
(	NULL
Washington	NULL
DC	NULL
)	NULL
,	NULL
249	NULL
;	NULL
1577-1580	NULL
,	NULL
1990	NULL
.	NULL

4	NULL
.	NULL

Grignani	NULL
,	NULL
F.	NULL
,	NULL
Fagioli	NULL
,	NULL
M.	NULL
,	NULL
Alcalay	NULL
,	NULL
M.	NULL
,	NULL
Longo	NULL
,	NULL
L.	NULL
,	NULL
Pandolfi	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
Donti	NULL
,	NULL
E.	NULL
,	NULL
Biondi	NULL
,	NULL
A.	NULL
,	NULL
Lo	NULL
Coco	NULL
,	NULL
F.	NULL
,	NULL
Grignani	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
Acute	NULL
promyelocytic	NULL
leukemia	NULL
:	NULL
from	NULL
genetics	NULL
to	NULL
treatment	NULL
.	NULL

Blood	NULL
,	NULL
83	NULL
:	NULL
10-25	NULL
,	NULL
1994	NULL
.	NULL

5	NULL
.	NULL

Gambacorti-Passerini	NULL
,	NULL
C.	NULL
Immunogenicity	NULL
of	NULL
fusion	NULL
proteins	NULL
:	NULL
an	NULL
example	NULL
of	NULL
tumor-specific/transformation-related	NULL
antigens	NULL
.	NULL

Int	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Lab	NULL
.	NULL

Res	NULL
.	NULL

,	NULL
23	NULL
:	NULL
186-191	NULL
,	NULL
1993	NULL
.	NULL

6	NULL
.	NULL

Gambacorti-Passerini	NULL
,	NULL
C.	NULL
,	NULL
Grignani	NULL
,	NULL
F.	NULL
,	NULL
Arienti	NULL
,	NULL
F	NULL
,	NULL
Pandolfi	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
and	NULL
Parmiani	NULL
,	NULL
G.	NULL
Human	NULL
CD4	NULL
lymphocytes	NULL
specifically	NULL
recognize	NULL
a	NULL
peptide	NULL
representing	NULL
the	NULL
fusion	NULL
region	NULL
of	NULL
the	NULL
hybrid	NULL
protein	NULL
pmI/RARa	NULL
present	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukaemia	NULL
cells	NULL
.	NULL

Blood	NULL
,	NULL
87	NULL
:	NULL
1369-1375	NULL
,	NULL
1993	NULL
.	NULL

7	NULL
.	NULL

Chen	NULL
,	NULL
W.	NULL
,	NULL
Peace	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Rovira	NULL
,	NULL
D.	NULL
K.	NULL
,	NULL
You	NULL
,	NULL
S-G.	NULL
,	NULL
and	NULL
Cheever	NULL
,	NULL
M.	NULL
A.	NULL
T-cell	NULL
immunity	NULL
to	NULL
the	NULL
joining	NULL
region	NULL
of	NULL
protein	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
89	NULL
:	NULL
1468-1472	NULL
,	NULL
1992	NULL
.	NULL

8	NULL
.	NULL

Gillis	NULL
,	NULL
S.	NULL
,	NULL
Ferm	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
Ou	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
Smith	NULL
,	NULL
K.	NULL
A.	NULL
T-cell	NULL
growth	NULL
factor	NULL
:	NULL
parameters	NULL
of	NULL
production	NULL
and	NULL
quantitative	NULL
microassay	NULL
for	NULL
activity	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
720	NULL
;	NULL
2027-2032	NULL
,	NULL
1978	NULL
.	NULL

9	NULL
.	NULL

Carballido	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Carballido-Perrig	NULL
,	NULL
N.	NULL
,	NULL
Terres	NULL
,	NULL
G.	NULL
,	NULL
Heusser	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
and	NULL
Blaser	NULL
,	NULL
K.	NULL
Bee	NULL
venom	NULL
phospholipase	NULL
A2	NULL
specific	NULL
T	NULL
cell	NULL
clones	NULL
from	NULL
human	NULL
allergic	NULL
and	NULL
non	NULL
allergic	NULL
individuals	NULL
:	NULL
cytokine	NULL
patterns	NULL
change	NULL
in	NULL
response	NULL
to	NULL
the	NULL
antigen	NULL
concentration	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
22	NULL
:	NULL
1357-1363	NULL
,	NULL
1992	NULL
.	NULL

10	NULL
.	NULL

Andersson	NULL
,	NULL
U.	NULL
,	NULL
Andersson	NULL
,	NULL
J.	NULL
,	NULL
Lindfors	NULL
,	NULL
A.	NULL
,	NULL
Wagner	NULL
,	NULL
K.	NULL
,	NULL
Moller	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Heusser	NULL
,	NULL
C.	NULL
H.	NULL
Simultaneous	NULL
production	NULL
of	NULL
interleukin	NULL
2	NULL
,	NULL
interleukin	NULL
4	NULL
and	NULL
interferon-y	NULL
by	NULL
activated	NULL
human	NULL
blood	NULL
lymphocytes	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
20	NULL
:	NULL
1591-1596	NULL
,	NULL
1990	NULL
.	NULL

11	NULL
.	NULL

Gambacorti-Passerini	NULL
,	NULL
C.	NULL
,	NULL
Rivoltini	NULL
,	NULL
L.	NULL
,	NULL
Supino	NULL
,	NULL
R.	NULL
,	NULL
Mariani	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Parmiani	NULL
,	NULL
G.	NULL
Differential	NULL
lysis	NULL
of	NULL
melanoma	NULL
clones	NULL
by	NULL
autologous	NULL
recombinant	NULL
interleukin	NULL
2-activated	NULL
lymphocytes	NULL
.	NULL

Relationship	NULL
with	NULL
spontaneous	NULL
resistance	NULL
to	NULL
doxorubicin	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
42	NULL
:	NULL
544-548	NULL
,	NULL
1988	NULL
.	NULL

12	NULL
.	NULL

Salter	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
and	NULL
Cresswell	NULL
,	NULL
P.	NULL
Impaired	NULL
assembly	NULL
and	NULL
transport	NULL
of	NULL
HLA-A	NULL
and	NULL
B	NULL
antigens	NULL
mutants	NULL
TxB	NULL
cell	NULL
hybrid	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
5	NULL
,	NULL
943-949	NULL
,	NULL
1986	NULL
.	NULL

13	NULL
.	NULL

Steinle	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Schendel	NULL
,	NULL
D.	NULL
J.	NULL
HLA	NULL
class	NULL
I	NULL
alleles	NULL
of	NULL
LCL	NULL
721	NULL
and	NULL
174xCEM	NULL
.	NULL

T2	NULL
(	NULL
T2	NULL
)	NULL
.	NULL

Tissue	NULL
Antigens	NULL
,	NULL
43	NULL
:	NULL
268-270	NULL
,	NULL
1994	NULL
.	NULL

14	NULL
.	NULL

De	NULL
la	NULL
Salle	NULL
,	NULL
H.	NULL
,	NULL
Hanau	NULL
,	NULL
D.	NULL
,	NULL
Fricker	NULL
,	NULL
D.	NULL
,	NULL
Urlacher	NULL
,	NULL
A.	NULL
,	NULL
Kelly	NULL
,	NULL
A.	NULL
,	NULL
Salamero	NULL
,	NULL
J.	NULL
,	NULL
Powis	NULL
,	NULL
S.	NULL
H.	NULL
,	NULL
Donato	NULL
,	NULL
L.	NULL
,	NULL
Bausinger	NULL
,	NULL
H.	NULL
,	NULL
Laforet	NULL
,	NULL
M.	NULL
,	NULL
Jeras	NULL
,	NULL
M.	NULL
,	NULL
Spehner	NULL
,	NULL
D.	NULL
,	NULL
Bieber	NULL
,	NULL
T.	NULL
,	NULL
Falkenrodt	NULL
,	NULL
A.	NULL
,	NULL
Cazenave	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Trowsdale	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Tongio	NULL
,	NULL
M.	NULL
M.	NULL
Homozygous	NULL
human	NULL
TAP	NULL
peptide	NULL
transporter	NULL
mutation	NULL
in	NULL
HLA	NULL
class	NULL
I	NULL
deficiency	NULL
.	NULL

Science	NULL
(	NULL
Washington	NULL
DC	NULL
)	NULL
,	NULL
265	NULL
:	NULL
237-241	NULL
,	NULL
1994	NULL
.	NULL

15	NULL
.	NULL

Mizoguchi	NULL
,	NULL
H.	NULL
,	NULL
O'Sheea	NULL
,	NULL
J.	NULL
,	NULL
Longo	NULL
,	NULL
D.	NULL
,	NULL
Loeffler	NULL
,	NULL
C.	NULL
,	NULL
McVicar	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Ochoa	NULL
,	NULL
A.	NULL
Alterations	NULL
in	NULL
signal	NULL
transduction	NULL
molecules	NULL
in	NULL
T	NULL
lymphocytes	NULL
from	NULL
tumor-bearing	NULL
mice	NULL
.	NULL

Science	NULL
(	NULL
Washington	NULL
DC	NULL
)	NULL
,	NULL
258	NULL
:	NULL
1795-1798	NULL
,	NULL
1992	NULL
.	NULL

16	NULL
.	NULL

Peace	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Smith	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Chen	NULL
,	NULL
W.	NULL
,	NULL
You	NULL
,	NULL
S-G.	NULL
,	NULL
Cosand	NULL
,	NULL
W.	NULL
L.	NULL
,	NULL
Blake	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Cheever	NULL
,	NULL
M.	NULL
A.	NULL
Lysis	NULL
of	NULL
ras	NULL
oncogene-transformed	NULL
cells	NULL
by	NULL
specific	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
elicited	NULL
by	NULL
primary	NULL
in	NULL
vitro	NULL
immunization	NULL
with	NULL
mutated	NULL
Ras	NULL
peptide	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
179	NULL
:	NULL
473-479	NULL
,	NULL
1994	NULL
.	NULL

17	NULL
.	NULL

Gedde-Dah	NULL
!	NULL

,	NULL
T.	NULL
,	NULL
IHI	NULL
,	NULL
Fossum	NULL
,	NULL
B.	NULL
,	NULL
Eriksen	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Thorsby	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Gaudernack	NULL
,	NULL
G.	NULL
T	NULL
cell	NULL
clones	NULL
specific	NULL
for	NULL
p21	NULL
ras-derived	NULL
peptides	NULL
:	NULL
characterization	NULL
of	NULL
their	NULL
fine	NULL
specificity	NULL
and	NULL
HLA	NULL
restriction	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
23	NULL
:	NULL
754-760	NULL
,	NULL
1993	NULL
.	NULL

18	NULL
.	NULL

Bocchia	NULL
,	NULL
M.	NULL
,	NULL
Wenworth	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Southwood	NULL
,	NULL
S.	NULL
,	NULL
Sidney	NULL
,	NULL
J.	NULL
,	NULL
McGraw	NULL
,	NULL
K.	NULL
,	NULL
Scheinberg	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Sette	NULL
,	NULL
A	NULL
.	NULL

Specific	NULL
binding	NULL
of	NULL
leukemia	NULL
oncogene	NULL
fusion	NULL
protein	NULL
peptides	NULL
to	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
.	NULL

Blood	NULL
,	NULL
85	NULL
:	NULL
2680-2685	NULL
,	NULL
1995	NULL
.	NULL

19	NULL
.	NULL

Turhan	NULL
,	NULL
A.	NULL
G.	NULL
,	NULL
Lemoine	NULL
,	NULL
F.	NULL
M.	NULL
,	NULL
Debert	NULL
,	NULL
C.	NULL
,	NULL
Bonnet	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
Baillou	NULL
,	NULL
C.	NULL
,	NULL
Picard	NULL
,	NULL
F.	NULL
,	NULL
Macintyre	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
and	NULL
Varet	NULL
,	NULL
B	NULL
.	NULL

Highly	NULL
purified	NULL
primitive	NULL
hematopoietic	NULL
stem	NULL
cells	NULL
are	NULL
PML-RARA	NULL
negative	NULL
and	NULL
generate	NULL
non-clonal	NULL
progenitors	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Blood	NULL
,	NULL
85	NULL
:	NULL
2154-2161	NULL
,	NULL
1995	NULL
.	NULL

20	NULL
.	NULL

Jinnai	NULL
,	NULL
I	NULL
.	NULL

In	NULL
vitro	NULL
growth	NULL
response	NULL
to	NULL
G-CSF	NULL
and	NULL
GM-CSF	NULL
by	NULL
bone	NULL
marrow	NULL
cells	NULL
of	NULL
patients	NULL
with	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
.	NULL

Leuk	NULL
.	NULL

Res	NULL
.	NULL

,	NULL
74	NULL
:	NULL
227-240	NULL
,	NULL
1990	NULL
.	NULL

21	NULL
.	NULL

Khanna-Gupta	NULL
,	NULL
A.	NULL
,	NULL
Kolibata	NULL
,	NULL
K.	NULL
,	NULL
Zibello	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Berliner	NULL
,	NULL
N.	NULL
NB4	NULL
cells	NULL
show	NULL
bilineage	NULL
potential	NULL
and	NULL
an	NULL
aberrant	NULL
pattern	NULL
of	NULL
neutrophil	NULL
secondary	NULL
granule	NULL
protein	NULL
gene	NULL
expression	NULL
.	NULL

Blood	NULL
,	NULL
84	NULL
:	NULL
294-302	NULL
,	NULL
1994	NULL
.	NULL

Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1996	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

AAGR	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
Clinical	NULL
Cancer	NULL
Research	NULL
Lack	NULL
of	NULL
T-cell-mediated	NULL
recognition	NULL
of	NULL
the	NULL
fusion	NULL
region	NULL
of	NULL
the	NULL
pmIl/RAR-alpha	NULL
hybrid	NULL
protein	NULL
by	NULL
lymphocytes	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
patients	NULL
.	NULL

S	NULL
Dermime	NULL
,	NULL
C	NULL
Bertazzoli	NULL
,	NULL
E	NULL
Marchesi	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Clin	NULL
Cancer	NULL
Res	NULL
1996	NULL
;	NULL
2:593-600	NULL
.	NULL

Updated	NULL
version	NULL
Access	NULL
the	NULL
most	NULL
recent	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//clincancerres.aacrjournals.org/content/2/3/593	NULL
E-mail	NULL
alerts	NULL
Reprints	NULL
and	NULL
Subscriptions	NULL
Permissions	NULL
Sign	NULL
up	NULL
to	NULL
receive	NULL
free	NULL
email-alerts	NULL
related	NULL
to	NULL
this	NULL
article	NULL
or	NULL
journal	NULL
.	NULL

To	NULL
order	NULL
reprints	NULL
of	NULL
this	NULL
article	NULL
or	NULL
to	NULL
subscribe	NULL
to	NULL
the	NULL
journal	NULL
,	NULL
contact	NULL
the	NULL
AACR	NULL
Publications	NULL
Department	NULL
at	NULL
pubs	NULL
@	NULL
aacr.org	NULL
.	NULL

To	NULL
request	NULL
permission	NULL
to	NULL
re-use	NULL
all	NULL
or	NULL
part	NULL
of	NULL
this	NULL
article	NULL
,	NULL
use	NULL
this	NULL
link	NULL
http	NULL
:	NULL
//clincancerres.aacrjournals.org/content/2/3/593	NULL
.	NULL

Click	NULL
on	NULL
``	NULL
Request	NULL
Permissions	NULL
``	NULL
which	NULL
will	NULL
take	NULL
you	NULL
to	NULL
the	NULL
Copyright	NULL
Clearance	NULL
Center	NULL
's	NULL
(	NULL
CCC	NULL
)	NULL
Rightslink	NULL
site	NULL
.	NULL

Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1996	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

